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ABSTRACT	  
Rheumatoid	  arthritis	  (RA)	  is	  a	  systemic	  inflammatory	  joint	  disease	  with	  at	  least	  two	  distinct	  
clinical	  phenotypes	  defined	  by	  the	  presence	  or	  absence	  of	  antibodies,	  i.e.	  rheumatoid	  factor	  
(RF)	  and/or	  anti-­‐citrullinated	  protein	  antibodies	  (ACPAs).	  These	  two	  phenotypes	  differ	  both	  
with	  respect	  to	  risk	  factors	  and	  disease	  outcome,	  with	  seropositive	  disease	  being	  more	  likely	  
associated	   with	   extra-­‐articular	   manifestations,	   such	   as	   lung	   manifestations,	   and	   tobacco	  
exposure.	  Both	  ACPA	  and	  RF	  can	  be	  detected	  in	  the	  blood	  years	  prior	  to	  the	  onset	  of	  joint	  
inflammation	  suggesting	  that	  these	  antibodies	  are	  initially	  generated	  outside	  the	  joints.	  The	  
current	  thesis	  investigates	  the	  pathogenic	  link	  between	  lungs	  and	  joints	  with	  a	  focus	  on	  the	  
potential	  role	  of	  the	  lung	  as	  an	  initiating	  site	  for	  the	  RA-­‐associated	  autoimmunity.	  
We	   investigated	   a	   cohort	   of	   patients	   with	   early,	   untreated	   RA,	   who	   underwent	   high	  
resolution	  computed	  tomography	  and	  conducted	   lung	  function	  tests.	  A	  subgroup	  of	  these	  
patients	  was	  subjected	  to	  bronchoscopy	  with	  retrieval	  of	  bronchoalveolar	  lavage	  (BAL)	  and	  
bronchial	   biopsies.	   All	   investigations	   were	   repeated	   after	   six	   months	   of	   anti-­‐rheumatic	  
treatment.	  
We	  found	  more	  prevalent	  lung	  abnormalities,	  both	  parenchymal	  (54%)	  and	  airway	  (66%)	  in	  
RA	   patients	   as	   compared	   to	   controls.	   The	   parenchymal	   abnormalities	   were	   significantly	  
more	   frequent	   in	   the	   subgroup	  of	  ACPA-­‐positive	  RA	  patients	   compared	   to	  ACPA-­‐negative	  
patients.	   The	   same	  was	   true	   after	   compensating	   for	   smoking.	   Signs	   of	   inflammation	   and	  
immune	   activation	   with	   more	   lymphocytic	   infiltration	   and	   expression	   of	   citrullinated	  
proteins	  were	  found	  in	  the	  lungs	  of	  ACPA-­‐positive	  as	  compared	  to	  ACPA-­‐negative	  patients.	  
ACPAs	  were	  enriched	  in	  the	  BAL	  as	  compared	  to	  the	  blood	  compartment	  of	  ACPA-­‐positive	  
patients.	  Using	  mass	  spectrometry	  we	  were	  able	  to	  identify	  two	  novel	  citrullinated	  vimentin	  
peptides	  that	  were	  present	  in	  a	  majority	  of	  bronchial	  (n=6)	  and	  RA	  synovial	  biopsies	  (n=7)	  
tested.	  Immune	  reactivity	  against	  these	  targets	  was	  specifically	  detected	  in	  the	  blood	  of	  RA	  
patients.	  At	  6	  months	  follow-­‐up	  one	  third	  of	  patients	  with	  lung	  fibrosis	  (11%)	  at	  baseline	  had	  
progressed	  and	  additionally	  3	  patients	  had	  developed	  new	  radiological	  changes	  suggestive	  
of	   early	   interstitial	   lung	   disease.	  Moreover,	   there	  was	   an	   increase	   in	   airway	   obstruction,	  
with	  a	  decline	  in	  forced	  expiratory	  volume	  in	  one	  second	  in	  all	  patients,	  more	  prominent	  in	  
smokers.	  	  
In	  conclusion,	  lung	  changes	  in	  early	  RA	  are	  prevalent	  and	  may	  be	  progressive	  despite	  anti-­‐
rheumatic	  treatment.	  Taken	  together	  our	  results	  support	  the	  hypothesis	  that	  the	  lung	  may	  
be	   an	   early	   important	   player	   in	   the	   pathogenesis	   of	   RA	   in	   a	   subset	   of	   patients.	   These	  
findings	  encourage	  new	  therapeutic	  strategies	  to	  target	  the	  local	  inflammation	  in	  the	  lungs,	  
with	  the	  aim	  to	  prevent	  the	  progress	  of	  autoimmunity	  in	  ACPA-­‐positive	  healthy	  individuals.	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  1 
1 INTRODUCTION	  
The	  aim	  of	  this	  thesis	  is	  to	  investigate	  the	  potential	  role	  of	  the	  lung	  in	  the	  pathogenesis	  of	  
autoimmunity	  in	  rheumatoid	  arthritis	  and	  to	  characterize	  the	  extent	  of	  lung	  changes	  in	  RA	  
at	  diagnosis.	  
1.1 RHEUMATOID	  ARTHRITIS	  
Rheumatoid	   arthritis	   (RA)	   is	   a	   chronic	   systemic	   inflammatory	   disease	   characterized	   by	  
peripheral	  joint	  inflammation.	  The	  prevalence	  of	  RA	  is	  about	  0.5-­‐1%	  in	  developed	  countries	  
and	  the	  annual	  incidence	  varies	  between	  20-­‐50	  cases	  per	  100,000	  inhabitants	  depending	  on	  
age	   and	   sex	   [1].	   RA	   is	   2-­‐3	   times	  more	   frequent	   in	  women	   and	   the	   usual	   age	   of	   onset	   is	  
between	  40-­‐70	  years	  with	  peak	  onset	  in	  the	  fifth	  decade	  of	  life	  [1,	  2].	  Patients	  with	  RA	  have	  
a	   reduced	   life	   expectancy	   compared	   to	   the	   general	   population	   [3],	   mainly	   due	   to	  
cardiovascular	  diseases	  [4,	  5]	  and	  secondly	  due	  to	  respiratory	  diseases	  [6].	  The	  presence	  of	  
extra-­‐articular	  manifestations	   in	   RA	   (reflecting	   the	   severity	   of	   systemic	   disease)	   has	   been	  
shown	  to	  be	  a	  major	  contributor	  to	  the	  excess	  mortality	  in	  RA	  [7].	  
1.1.1 	  	  	  	  Clinical	  features	  and	  diagnosis	  
The	   clinical	   course	   of	   RA	   is	   variable,	   ranging	   from	   a	   mild	   to	   rapidly	   progressive	   erosive	  
disease.	   The	  onset	   is	   usually	   insidious	  with	   symmetrical	   swelling	  and	  pain	  of	   the	   joints	   in	  
hands	   and	   feet	   and	  morning	   stiffness.	   If	   left	   untreated	   irreversible	   joint	   destruction	  may	  
occur	  with	  subsequent	  functional	  disability	  and	  decreased	  quality	  of	  life.	  General	  symptoms	  
such	   as	   low-­‐grade	   fever,	  malaise	   and	   fatigue	   can	   also	   be	   experienced	   and	   in	   some	   cases	  
extra-­‐articular	  symptoms	  may	  predate	  the	  joint	  disease	  [8].	  	  
The	   diagnosis	   of	   RA	   is	   still	   today	   based	   on	   a	   set	   of	   criteria	   due	   to	   the	   lack	   of	   a	   specific	  
diagnostic	  test.	  The	  classification	  criteria	  from	  the	  American	  College	  of	  Rheumatology	  (ACR)	  
from	  1987	   (Table	  1),	   [9],	  originally	   created	   for	   research	  purposes,	  have	  been	  widely	  used	  
internationally	   as	   a	  diagnostic	   tool.	  During	  2010	  updated	   criteria	  were	   issued	  by	   the	  ACR	  
and	   the	   European	   League	   Against	   Rheumatism	   (EULAR)	   in	   order	   to	   allow	   for	   earlier	  
diagnosis	  of	  RA	  (Table	  2)	  [10].	  Inclusion	  of	  all	  patients	  included	  in	  the	  studies	  presented	  in	  
this	   thesis	  was	   performed	   between	   2007	   and	   2012	   and	   therefore	   the	   1987	   criteria	  were	  
used.	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Table	  1.	  The	  ACR	  classification	  criteria	  for	  RA	  (1987)	  
Criterion	  
1.	  Morning	  stiffness	  
2.	  Arthritis	  of	  ≥3	  joint	  areas	  
3.	  Arthritis	  of	  hand	  joints	  
4.	  Symmetric	  arthritis	  
5.	  Rheumatoid	  nodules	  
6.	  Rheumatoid	  factor	  
7.	  Radiographic	  changes	  
Patients	   fulfilling	   at	   least	   4/7	   criteria	   are	   classified	   as	   having	  RA.	   Criteria	   1-­‐4	  must	   be	  present	   for	   at	   least	   6	  
weeks.	  
Table	  2.	  The	  ACR/EULAR	  classification	  criteria	  for	  RA	  (2010)	  
A.	  Joint	  involvement	   Score	  
1	  large	  joint	   0	  
2-­‐10	  large	  joint	   1	  
1-­‐3	  small	  joints	  (with	  or	  without	  involvement	  of	  large	  joints)	   2	  
4-­‐10	  small	  joints	  (with	  or	  without	  involvement	  of	  large	  joints)	   3	  
>10	  joints	  (at	  least	  1	  small	  joint)	  	   5	  
Serology	  (at	  least	  1	  test	  result	  is	  needed	  for	  classification)	   Score	  
Negative	  RF	  and	  negative	  ACPA	   0	  
Low-­‐positive	  RF	  or	  low	  positive	  ACPA	   2	  
High-­‐positive	  RF	  or	  high-­‐positive	  ACPA	   3	  
C.	  Acute-­‐phase	  reactants	  (at	  least	  1	  test	  result	  is	  needed	  for	  classification)	   Score	  
Normal	  C-­‐reactive	  protein	  (CRP)	  and	  normal	  erythrocyte	  sedimentation	  rate	  (ESR)	   0	  
Abnormal	  CRP	  or	  abnormal	  ESR	   1	  
D.	  Duration	  of	  symptoms	   Score	  
<6	  weeks	   0	  
≥6	  weeks	   1	  
Target	  population:	  Patients	  who	  1)	  have	  at	   least	  1	   joint	  with	  definite	   clinical	   synovitis	   (swelling)	  2)	  with	   the	  
synovitis	  not	  better	  explained	  by	  another	  disease.	  To	  be	  classified	  as	  rheumatoid	  arthritis,	  an	  overall	  score	  of	  ≥	  
6/10	  is	  required.	  
1.1.2 	  	  	  	  Autoantibodies	  in	  RA	  and	  phenotypes	  
RA	  is	  an	  autoimmune	  disease	  traditionally	  divided	  into	  two	  subsets	  based	  on	  the	  presence	  
or	  absence	  of	  autoantibodies.	  The	  classic	  antibody	  related	  to	  RA	  is	  rheumatoid	  factor	  (RF),	  
first	  described	  in	  1939	  [11].	  RF	  is	  antibodies	  against	  the	  Fc	  portion	  of	  IgG	  that	  are	  evident	  in	  
about	  70%	  of	  all	  patients	  with	  RA	  [12].	  RF	  can	  also	  be	  detected	  in	  other	  autoimmune	  and	  
infectious	   diseases	   as	   well	   as	   in	   healthy	   individuals,	   thereby	   diminishing	   its	   diagnostic	  
specificity	  [13].	  The	  later	  discovered	  and	  more	  specific	  biomarker	  in	  RA	  is	  anti-­‐citrullinated	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peptide	  antibodies	  (ACPAs)	  [14].	  These	  antibodies	  can	  be	  detected	  in	  approximately	  70%	  of	  
RA	  patients,	  but	  have	  a	  much	  higher	  specificity	  (94-­‐98%)	  than	  RF	  [15].	  The	  ACPA	  pool	  in	  RA	  
patients	   is	  heterogeneous,	  with	  antibody	  reactivities	  against	  multiple	  citrullinated	  proteins	  
differing	   between	   individual	   patients	   [16].	   Details	   about	   the	   citrullination	   process,	   the	  
different	   ACPA	   specificities	   and	   their	   potential	   role	   in	   RA	   pathogenesis	   will	   be	   discussed	  
further	   in	   chapter	   1.3.	   The	   standard	   test	   to	   measure	   the	   presence	   of	   ACPAs	   in	   clinical	  
practice	  is	  a	  commercial	  anti-­‐cyclic	  citrullinated	  peptide	  (anti-­‐CCP)	  immunoassay.	  The	  anti-­‐
CCP	   test	   covers	   reactivities	   against	  multiple	   citrullinated	   protein	   targets	   [17].	   The	   second	  
generation	  of	  anti-­‐CCP	  has	  been	  demonstrated	  to	  have	  a	  high	  sensitivity	  and	  specificity	  [18]	  
and	  is	  the	  test	  used	  to	  categorize	  RA	  patients	  in	  the	  studies	  presented	  in	  this	  thesis.	  	  
More	   recently	   identified	   are	   antibodies	   against	   carbamylated	   proteins,	   which	   are	  
homocitrulline	  containing	  antibodies.	  These	  antibodies,	  not	  yet	  used	  in	  clinical	  practice,	  are	  
present	  in	  a	  majority	  of	  ACPA-­‐positive	  patients	  but	  also	  in	  about	  15%	  of	  patients	  with	  ACPA-­‐
negative	  RA	  [19].	  Interestingly,	  ACPAs,	  RF	  and	  antibodies	  against	  carbamylated	  proteins	  may	  
be	  present	  several	  years	  before	  disease	  onset	  [20-­‐23].	  	  
Following	  the	  discovery	  of	  ACPAs,	  given	  their	  specificity	  for	  RA	  as	  well	  as	  their	  presence	  in	  
blood	  years	  before	  symptoms,	  research	  in	  the	  field	  of	  RA	  has	  focused	  on	  these	  antibodies.	  
Studies	   have	   demonstrated	   that	   patients	  with	   ACPA-­‐positive	   disease	   differ	   from	   patients	  
with	  ACPA-­‐negative	  disease	  with	  respect	  to	  genetic	  and	  environmental	  risk	  factors	  (Figure	  1)	  
[24].	  In	  addition,	  presence	  of	  ACPA	  has	  been	  associated	  with	  a	  more	  severe	  disease	  course	  
and	  more	  joint	  destruction	  [25-­‐27].	  	  
	  
	  
Figure	  1.	  Differences	  between	  ACPA-­‐positive	  and	  ACPA-­‐negative	  RA	  patients	  
	  
Adapted	  from	  Klareskog	  et	  al	  [24].	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1.1.3 	  	  	  	  Disease	  activity	  
Assessment	  of	  disease	  activity	  is	  crucial	  in	  the	  management	  of	  RA	  patients	  and	  needs	  to	  be	  
done	   on	   a	   regular	   basis.	   Since	   there	   is	   no	   single	   test	   available	   the	   disease	   activity	  
assessment	   includes	   examination	   of	   joints	   with	   respect	   to	   tenderness	   and	   swelling	   and	  
measurement	  of	   inflammatory	  markers,	  such	  as	  erythrocyte	  sedimentation	  rate	   (ESR)	  and	  
C-­‐reactive	   protein	   (CRP).	   These	   measurements	   are	   not	   without	   limitations,	   however,	   as	  
many	  patients	  with	  RA	  have	  normal	  values	  despite	  existing	  joint	  inflammation	  [28].	  	  
The	  most	   widely	   used	   assessment	   tool	   of	   disease	   activity	   is	   the	   28-­‐joint	   disease	   activity	  
score	  (DAS28),	  originally	  developed	  to	  evaluate	  treatment	  outcome	  in	  clinical	  trials	  [29].	  This	  
is	   a	   composite	   index	   that	   includes	   numbers	   of	   swollen	   and	   tender	   joints	   (28	   joints),	   a	  
measurement	  of	  ESR	  and	  the	  patient’s	  general	  health	  assessment	  on	  a	  visual	  analogue	  scale	  
(0-­‐100).	  DAS28	  has	  also	  been	  modified	  to	   include	  CRP	  instead	  of	  SR,	  since	  CRP	   levels	  may	  
better	  reflect	  acute	  inflammation	  than	  levels	  of	  ESR	  [30].	  The	  outcome	  of	  DAS28	  is	  used	  to	  
define	  disease	  activity	  as	  low,	  moderate	  or	  high	  [31].	  The	  main	  limitation	  of	  DAS28	  is	  that	  it	  
does	  not	   include	   the	   joints	   in	   the	   feet	   and	   therefore	  may	  underestimate	  disease	  activity.	  
Furthermore,	  ESR	  levels	  can	  be	  increased	  due	  to	  other	  medical	  conditions	  and	  the	  patient’s	  
global	   assessment	   can	   also	   be	   influenced	   by	   factors	   other	   than	   those	   caused	   by	   the	  
inflammatory	  disease.	  One	  should	  thus	  always	  consider	  what	  underlies	  the	  value	  of	  DAS28.	  
Other	  assessment	  tools	  such	  as	  patient-­‐reported	  questionnaires	  of	  physical	  function	  (Health	  
Assessment	  Questionnaire,	  HAQ)	  and	  assessment	  of	  radiographic	  progression	  are	  also	  used	  
routinely	  in	  clinical	  practice	  [32,	  33].	  
1.1.4 	  	  	  	  Treatment	  
There	   has	   been	   a	   paradigm	   shift	   in	   the	  management	   and	   treatment	   of	   patients	  with	   RA	  
during	   the	   last	   20	   years.	   A	   combination	   of	   factors	   has	   contributed	   to	   this,	   such	   as	   an	  
increased	  awareness	  and	  the	  possibility	  of	  diagnosing	  patients	  at	  an	  earlier	  stage	  as	  well	  as	  
the	   understanding	   of	   the	   importance	   to	   initiate	   anti-­‐rheumatic	   treatment	   as	   soon	   as	   a	  
diagnosis	  is	  set	  in	  order	  to	  avoid	  future	  disability.	  Additionally,	  there	  is	  increased	  knowledge	  
on	  how	  to	  use	  the	  older	  medications	  and	  new	  biological	  treatments	  have	  come	  into	  use	  [34,	  
35].	  	  
Today	   there	   are	   two	  major	   classes	   of	   disease-­‐modifying	   anti-­‐rheumatic	   drugs	   (DMARDs);	  
the	   conventional	   synthetic	   DMARDs	   (csDMARD)	   which	   include	   methotrexate	   (MTX),	  
sulfasalazine	  and	  leflunomide,	  and	  the	  biological	  DMARDs	  (bDMARD)	  which	  include	  tumour	  
necrosis	  factor	   inhibitors	  (TNFi)	  (adalimumab,	  certolizumab	  pegol,	  etanercept,	  golimumab,	  
infliximab),	  a	  T	  cell	  costimulation	   inhibitor	   (abatacept),	  an	  anti-­‐B	  cell	  agent	  (rituximab),	  an	  
interleukin-­‐6	   receptor	   (IL-­‐6R)	   blocking	   monoclonal	   antibody	   (tocilizumab),	   and	   an	   IL-­‐1	  
inhibitor	  (anakinra).	  	  
Methotrexate	   is	   the	   mainstay	   of	   initial	   treatment	   but	   in	   case	   of	   intolerance	   or	  
contraindications	   sulfasalazine	   or	   leflunomide	   are	   alternatives.	  Glucocorticoids	   have	   been	  
debated	   for	   a	   long	   time	   due	   to	   the	   known	   detrimental	   effects	   especially	   related	   to	   high	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doses	  and	  long-­‐term	  use.	   In	  contrast,	  the	  good	  effect	  of	   low	  dose	  glucocorticoids	  on	  both	  
disease	  activity	  and	  radiographic	  progression	  justify	  their	  use	  as	  part	  of	  the	  initial	  treatment	  
[36].	   If	   low	   disease	   activity	   is	   not	   achieved	   after	   3	   months	   of	   treatment	   with	   MTX	   the	  
therapy	   needs	   to	   be	   intensified.	   Either	   addition	   of	   other	   csDMARDs	   (such	   as	  
hydroxychloroquine	   and	   sulfasalazine)	   or	   bDMARD	   (in	   the	   first	   place	   TNFi,	   but	   also	  
abatacept,	  tocilizumab	  or	  rituximab)	  should	  always	  be	  considered	   in	  the	  presence	  of	  poor	  
prognostic	   factors,	   such	   as	   ACPA	   and/or	   RF	   positivity,	   high	   disease	   activity	   or	   early	  
radiographic	  changes	  [37].	  	  
This	   important	   development	   in	   treatment	   enables	   us	   to	   set	   the	   goal	   high,	  which	   for	   the	  
patient	  means	   achieving	   clinical	   remission	  or	   low	  disease	  activity,	   thereby	  minimizing	   the	  
risk	  for	  joint	  destruction	  with	  functional	  disability	  and	  maximizing	  RA-­‐related	  quality	  of	  life.	  
Future	   hope	   is	   to	   be	   able	   to	   further	   individualize	   treatment	   options,	   for	   example	   on	   the	  
basis	  of	  absence	  or	  presence	  of	  specific	  biomarkers.	  	  
1.1.5 	  	  	  	  Extra-­‐articular	  manifestations	  
RA	   is	   a	   systemic	   disease	   with	   approximately	   40%	   of	   patients	   having	   extra-­‐articular	  
manifestations	   (ExRA)	  over	   the	   course	  of	   the	  disease	   [38-­‐40].	   ExRA	  can	  affect	  almost	  any	  
structure	  in	  the	  body,	  causing	  e.g.	  rheumatic	  nodules,	  opthalmic	  disease,	  vascular	  disease,	  
cardiopulmonary	  manifestations,	   kidney	  disease	   and	  neurological	  manifestations	   [38,	   41].	  
Usually	   these	   systemic	  manifestations	  are	  considered	  markers	  of	  disease	   severity	  and	  are	  
associated	  with	  significant	  morbidity	  and	  increased	  mortality	  [7,	  40,	  42,	  43].	  	  
Previous	   studies	   have	   demonstrated	   that	   age,	   smoking,	   positive	   serology	   (both	   RF	   and	  
ACPA),	   presence	   of	   the	   genetic	   risk	   factor	   human	   leukocyte	   antigen	   (HLA)-­‐DR	   shared	  
epitope,	  and	  severe	  disease	  activity	  are	  risk	  factors	  for	  ExRA	  [8,	  44-­‐46].	  The	  presence	  of	  RF	  is	  
more	  strongly	  associated	  with	  extra-­‐articular	  manifestations	  than	  anti-­‐CCP	  antibodies	  [47].	  
This	  may	  be	  explained	  by	  the	  high	  levels	  of	  circulating	  immune	  complexes	  that	  have	  been	  
detected	  in	  these	  patients	  [48]	  and	  the	  potential	  role	  of	  RF	  in	  the	  formation	  of	  complement	  
activating	   immune	   complexes	   [47].	   However,	   a	   recent	   study	   found	   even	   stronger	  
associations	  with	  the	  presence	  of	  antibodies	  against	  mutated	  citrullinated	  vimentin	  (MCV)	  
[49],	   suggesting	  a	  possible	   role	  of	  citrullination	  and	  specific	  anti-­‐citrulline	   immunity	   in	   the	  
pathogenesis	  of	  extra-­‐articular	  involvement.	  	  
The	  optimal	  management	  of	  ExRA	   is	  not	  known	  and	  recommendations	  are	  based	  on	  case	  
reports	  and	  expert	  opinions.	  The	  general	  approach	   is	   to	  treat	   the	  underlying	   joint	  disease	  
aggressively.	  In	  cases	  where	  joint	  inflammation	  is	  low	  and/or	  extra-­‐articular	  manifestations	  
dominate	   (e.g.	   vasculitis)	   treatment	   usually	   includes	   glucocorticoids	   and	   immuno-­‐
suppressive	  agents	  [50].	  	  
Although	  the	  majority	  of	  ExRA	  manifestations	  occur	  as	  a	  complication	  of	  RA,	  some	  of	  these	  
manifestations	  can	  present	  at	  or	  before	  joint	  inflammation.	  This	  is	  particularly	  the	  case	  with	  
lung	  manifestations	  [8].	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1.2 LUNG	  MANIFESTATIONS	  IN	  RA	  
It	   is	   common	   knowledge	   among	   rheumatologists	   and	   pulmonologists	   that	   lung	   diseases	  
often	  accompany	  RA.	  The	  reported	  prevalence	  of	  lung	  abnormalities	  in	  RA	  varies	  between	  
studies	   from	   10-­‐67%,	   depending	   on	   the	   mode	   of	   investigation	   (HRCT	   versus	   chest	  
radiography),	   definition	   of	   lung	   disease	   as	   well	   as	   the	   RA	   population	   under	   study	   (early	  
versus	   longstanding)	   [51-­‐54].	   Moreover,	   lung	   diseases	   are	   a	   significant	   contributor	   to	  
increased	  mortality	  in	  RA	  patients,	  accounting	  for	  about	  10%	  of	  deaths	  in	  RA	  and	  making	  it	  
the	  second	   leading	  cause	  of	  death	   in	  this	  patient	  group	  [6,	  47,	  55-­‐57]	  after	  cardiovascular	  
diseases	  [4,	  5].	  	  
The	   spectrum	   of	   pleuropulmonary	   manifestations	   in	   RA	   is	   broad,	   ranging	   from	   pleural	  
disease	  and	  airways	  obstruction	  to	  severe	  interstitial	  lung	  disease	  (ILD)	  (Table	  3)	  [58-­‐61].	  
Table	  3.	  Pleuropulmonary	  manifestations	  associated	  with	  rheumatoid	  arthritis	  















Chest	  wall	  disease	  
Lung	  cancer	  
COPD	  =	  chronic	  obstructive	  pulmonary	  disease,	  PH	  =	  pulmonary	  hypertension	  RA-­‐ILD	  =	  rheumatoid	  
arthritis	  associated	  interstitial	  lung	  disease.	  
Typically	   these	   manifestations	   are	   considered	   a	   complication	   of	   arthritis	   disease,	   but	   in	  
some	  cases	  lung	  disease	  predates	  joint	  inflammation	  and	  predominates	  the	  clinical	  picture	  
[56,	   62].	   The	   clinical	   interpretation	   of	   RA	   patients	   with	   lung	   symptoms	   is	   further	  
complicated	   by	   the	   fact	   that	   many	   of	   the	   treatment	   alternatives	   for	   RA	   can	   induce	  
pulmonary	   changes.	   In	   addition,	   patients	   with	   systemic	   disease	   are	   more	   susceptible	   to	  
infections	   and	   immunosuppressive	  medications	   further	   increase	   this	   risk.	   Taken	   together	  
this	   imposes	  a	  great	   challenge	   to	  attending	  clinicians	  and	   the	   importance	  of	  good	  history	  
and	  clinical	  assessment	  cannot	  be	  underestimated	  [63].	  
The	   investigations	   most	   commonly	   used	   to	   evaluate	   lung	   involvement	   are	   chest	  
radiography,	   high	   resolution	   computed	   tomography	   (HRCT)	   and	   pulmonary	   function	   test	  
(PFT).	  HRCT	  has	  a	  clear	  superiority	  over	  chest	  radiography	  and	  PFT	  in	  detecting	  subtle	  lung	  
changes	   [64].	   PFTs	   (dynamic	   spirometry,	   lung	   volumes	   and	   diffusing	   capacity	   for	   carbon	  
monoxide	   (DLCO))	   are	   often	   used	   to	   follow	   lung	   function	   and	   in	   differentiating	   between	  
obstructive	  and	  restrictive	  disease.	  The	  most	  practical	  parameters	  to	  have	  in	  mind	  are	  total	  
lung	  capacity	  (TLC),	  forced	  expiratory	  volume	  in	  1	  second	  (FEV1),	  forced	  vital	  capacity	  (FVC)	  
and	  the	  ratio	  between	  these	  two.	  A	  low	  FEV1/FVC	  indicates	  obstructive	  disease,	  whereas	  a	  
normal	  or	  high	  ratio	  in	  the	  presence	  of	  low	  TLC	  is	  generally	  suggestive	  of	  restrictive	  disease.	  
Diffusion	  capacity	  for	  carbon	  monoxide	  (DLCO)	  assesses	  gas	  exchange	  and	  in	  the	  context	  of	  
restrictive	  lung	  disease,	  reduced	  DLCO	  indicates	  intrinsic	  lung	  disease.	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1.2.1 	  	  	  	  Airway	  changes	  
The	   most	   sensitive	   detection	   method	   for	   airway	   changes	   is	   HRCT.	   Not	   all	   comparative	  
studies	  have	  reported	  a	  correlation	  between	  HRCT	  and	  lung	  function	  testing,	  since	  the	  latter	  
may	   not	   change	   until	   advanced	   disease	   [54].	   Frequent	   features	   of	   clinically	   manifested	  
airway	   disease	   are	   cough,	   dyspnea	   on	   exertion	   and	   in	   certain	   cases	   an	   increased	   risk	   for	  
infections.	  
1.2.1.1 Upper	  airway	  obstruction	  
The	  main	  cause	  for	  this	  condition	  in	  RA	  is	  cricoarythenoid	  arthritis,	  which	  is	  more	  common	  
in	  women	  and	  in	  longstanding	  disease.	  It	  can	  go	  unrecognized	  due	  to	  the	  late	  appearance	  of	  
symptoms.	   Treatment	   aims	   to	   control	   inflammation	   and	   in	   cases	   of	   severe	   obstruction	  
surgical	  intervention	  may	  be	  needed	  [65].	  
1.2.1.2 Small	  airway	  obstruction	  
This	  condition	  can	  occur	  as	  a	  lone	  manifestation	  or	  in	  combination	  with	  RA-­‐ILD.	  Prevalence	  
is	  quite	  high	  on	  HRCT	  and	  often	  without	  physiological	  abnormality.	  The	  clinical	  significance	  
and	   natural	   history	   are	   unknown.	   Perez	   et	   al	   found	   a	   correlation	   between	   small	   airways	  
disease	  and	  bronchiectasis	  and	  bronchial	  wall	  thickening	  [66].	  	  
1.2.1.3 Obliterative	  bronchiolitis	  (OB)	  
OB	  is	  a	  rare	  and	  severe	  complication	  of	  RA	  and	  should	  be	  suspected	  in	  cases	  of	  abrupt	  onset	  
of	   severe	  dyspnea	  and	  cough.	   It	   is	  more	  common	   in	  women	  and	   in	  association	  with	  high	  
levels	  of	  RF.	  It	  has	  also	  been	  described	  as	  an	  adverse	  reaction	  to	  anti-­‐rheumatic	  drugs	  such	  
as	  penicillamin	  and	  sulfasalazine	  [67].	  The	  HRCT	  image	  of	  OB	  includes	  signs	  of	  bronchial	  wall	  
thickening,	   centrilobular	   emphysema	  and	  bronchiectasis	   [68].	  OB	   is	   usually	   regarded	   as	   a	  
consequence	  of	  arthritis	  disease	  but	  one	  case	  report	  described	  the	  presence	  of	  OB	  in	  at-­‐risk	  
individual	  with	  high	  RF	  levels	  but	  no	  joint	  inflammation	  [69].	  
1.2.1.4 Follicular	  bronchiolitis	  
Follicular	   bronchiolitis	   consists	   of	   lymphoid	   hyperplasia	   of	   bronchus-­‐associated	   lymphoid	  
tissue	  and	  can	  be	  found	  in	  combination	  with	  ILD	  and	  can	  also	  accompany	  other	  rheumatic	  
diseases	   [70].	   High	   levels	   of	   RF	   are	   usually	   present.	   Interestingly,	   one	   report	   from	   Japan	  
described	   one	   case	   in	  which	   follicular	   bronchiolitis	   preceded	   joint	   inflammation	   [71],	   but	  
this	   condition	   is	   usually	   considered	   a	   complication	   of	   longstanding	   RA.	   HRCT	   signs	   are	  
centrilobular	  or	  peribronchial	  micronodules,	  bronchial	  dilation	  and	  bronchial	  wall	  thickening	  
[72].	  	  
1.2.1.5 Bronchiectasis	  
Bronchiectasis	  are	  apparent	  in	  about	  30%	  of	  RA	  patients	  when	  detected	  by	  HRCT	  [73],	  and	  is	  
thus	   one	   of	   the	   most	   frequent	   lung	   abnormalities	   evident	   in	   RA	   patients.	   However,	  
symptomatic	  bronchiectasis	   is	  only	  recorded	   in	  2.7%	  of	  RA	  patients	  [74].	  Patients	  with	  RA	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and	  co-­‐existent	  clinically	  manifest	  bronchiectasis	  have	  an	  increased	  mortality	  rate,	  7.3	  times	  
that	   of	   the	   general	   population	   [75].	   A	   recent	   study	   in	   RA	   patients	   with	   concomitant	  
symptomatic	  bronchiectasis	  found	  higher	  disease	  activity,	  disease	  severity	  and	  presence	  of	  
anti-­‐CCP	  and	  RF	  as	   compared	   to	  patients	  with	  RA	  alone	   [76].	   Interestingly,	  one	  old	   study	  
described	  appearances	  of	  bronchiectasis	  before	  joint	  inflammation	  [77],	  and	  this	  has	  been	  
recently	  confirmed	  in	  a	  new	  study	  in	  which	  bronchiectasis	  was	  observed	  to	  precede	  RA	  in	  
about	  half	  of	  the	  cases	  [76].	  
1.2.1.6 Obstructive	  lung	  disease	  (OLD)	  
A	  study	  from	  Nannini	  et	  al	  of	  the	  prevalence	  of	  OLD	  in	  RA	  patients	  demonstrated	  a	  higher	  
risk	  of	  OLD	  in	  RA	  patients	  with	  associated	  higher	  mortality,	  as	  compared	  to	  non-­‐RA	  subjects	  
[78].	   The	   diagnosis	   of	   OLD	   was	   based	   on	   FEV1/FVC	   <	   0.7	   and	   included	   the	   diagnosis	   of	  
COPD,	  asthma,	  ILD	  with	  airway	  obstruction	  and	  bronchiectasis.	  Another	  study	  from	  Taiwan	  
has	  also	  reported	  a	  significantly	  higher	  risk	  of	  developing	  COPD	  in	  RA	  patients	  as	  compared	  
to	  in	  non-­‐RA	  individuals	  [79].	  	  	  
1.2.2 	  	  	  	  Parenchymal	  diseases	  	  
1.2.2.1 Rheumatoid	  lung	  nodules	  	  
Studies	  have	  shown	  a	  wide	  prevalence	  of	   lung	  nodules	   ranging	   from	  4%	   [80]	   to	  32%	   [81]	  
depending	   on	   the	   diagnostic	   mode	   of	   investigation.	   Generally	   lung	   nodules	   are	   more	  
common	   in	   patients	   with	   longstanding	   disease,	   the	   presence	   of	   autoantibodies	   and	  
concomitant	   subcutaneous	   rheumatoid	   nodules.	   They	   are	   usually	   asymptomatic	   but	   can	  
rupture	  into	  the	  pleural	  cavity	  and	  cause	  pneumothorax,	  effusion	  and	  infection.	  The	  general	  
prognosis	   is	  good	  in	  most	  cases	  with	  occasional	  spontaneous	  disappearance	  of	  nodules.	  A	  
main	  concern	  is	  to	  differentiate	  rheumatoid	  lung	  nodules	  from	  lung	  cancer	  [82].	  
1.2.2.2 Caplan	  syndrome	  	  
In	  1953	  Caplan	  described	  the	  association	  between	  pneumoconiosis	   in	  coal	  miners	  and	  RA	  
[83].	  Since	  then	  Caplan	  syndrome	  has	  been	  described	  in	  individuals	  exposed	  to	  dust	  such	  as	  
silica	  and	  asbestos	  [84].	  The	  majority	  of	  patients	  with	  this	  association	  are	  RF-­‐positive	  [84].	  
1.2.2.3 Pleural	  disease	  
Pleural	  disease	  is	  common	  among	  RA	  patients,	  autopsy	  studies	  revealing	  a	  prevalence	  of	  38-­‐
73%,	   but	   mainly	   subclinical	   disease.	   This	   is	   more	   common	   in	   the	   male	   gender	   and	   in	  
longstanding	  disease,	  but	  can	  precede	  the	  joint	  inflammation	  and	  often	  coexists	  with	  other	  
RA-­‐associated	  lung	  diseases	  [84].	  
1.2.2.4 Drug-­‐induced	  lung	  disease	  
Most	  of	  the	  DMARDs	   in	  use	  today	  can	   lead	  to	  drug-­‐induced	   lung	  diseases	  with	   impact	  on	  
morbidity	  and	  mortality	  in	  RA	  [85].	  These	  manifestations	  can	  present	  acutely	  or	  subacutely	  
and	   vary	   in	   severity.	   The	   most	   common	   complications	   are	   infections	   (bacterial	   and	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opportunistic)	  [86,	  87],	  diffuse	  interstitial	  processes	  [88]	  and	  less	  commonly	  airway	  disease	  
[67].	  	  
Methotrexate	   (MTX)	   is	   the	  drug	  most	  commonly	   implicated	   in	  drug-­‐induced	  pneumonitis,	  
progression	   of	   underlying	   RA-­‐ILD	   or	   fibrosis	   [89,	   90].	   The	   likelihood	   of	   developing	  
pneumonitis	  during	  MTX	  treatment	  has	  been	  estimated	  to	  be	  0.3-­‐11%	  and	  pre-­‐existing	  lung	  
disease	   is	   one	   of	   the	   risk	   factors	   [89,	   91].	   Patients	   usually	   respond	   quite	   well	   to	   drug	  
withdrawal	  or	  treatment	  with	  glucocorticoids.	  However,	  some	  studies	  have	  reported	  about	  
a	  20%	   increase	   in	  mortality	   rate	   for	   the	  affected	  patients,	   especially	   if	   the	   toxicity	  occurs	  
during	  the	  first	  6	  months	  of	  treatment	  [88,	  91,	  92].	  Prolonged	  use	  of	  MTX	  has	  been	  related	  
to	  mild	  reduction	  in	  lung	  capacity	  values,	  although	  this	  has	  not	  been	  found	  to	  be	  clinically	  
important	  [63,	  92].	  Similar	  to	  MTX,	  leflunomide	  can	  also	  cause	  pneumonitis,	  in	  particular	  in	  
those	  individuals	  with	  severe	  interstitial	  lung	  disease,	  and	  is	  not	  recommended	  to	  patients	  
with	  previous	  history	  of	  lung	  toxicity	  due	  to	  Methotrexate	  [93,	  94].	  	  
Case	  reports	  have	  related	  bDMARDs-­‐induced	  pneumonitis	  with	  high	  mortality	  in	  RA	  patients	  
[88],	   particularly	   in	   those	  with	   pre-­‐existing	   lung	   disease	   [95].	   However,	   the	   prevalence	   is	  
thought	  to	  be	  low	  and	  some	  case	  reports	  have	  described	  improvement	  in	  RA-­‐ILD	  following	  
treatment	  with	  biologics	  [96].	  Reports	  on	  the	  association	  between	  newer	  biologics,	  such	  as	  
tocilizumab,	  and	  ILD	  have	  been	  conflicting	  [97,	  98].	  	  
Overall	   the	   risk	   of	   pneumonitis	   due	   to	   MTX,	   leflunomide	   or	   TNF	   inhibitors	   has	   been	  
estimated	   to	   be	   low	   (about	   1%)	   and	   is	   particularly	   related	   to	   pre-­‐existing	   lung	   disease.	  
Controlled	  studies	  are	  needed	  regarding	  safety	  in	  treating	  RA	  patients	  with	  concomitant	  ILD	  
[97,	  98].	  
1.2.3 	  	  	  	  RA-­‐associated	  interstitial	  lung	  disease	  (RA-­‐ILD)	  
The	   most	   common	   and	   severe	   lung	   manifestation	   associated	   with	   RA	   is	   interstitial	   lung	  
disease	  (RA-­‐ILD).	  As	  mentioned	  above	  the	  reported	  prevalence	  varies	  and	  depends	  on	  the	  
mode	   of	   investigation,	   the	   definition	   of	   lung	   disease	   as	  well	   as	   the	   RA	   population	   under	  
study.	   Gabbay	   et	   al	   described	   lung	   abnormalities	   consistent	   with	   ILD	   in	   6%	   using	   chest	  
radiography	   versus	   33%	   using	   HRCT	   in	   early	   arthritis	   patients	   receiving	   anti-­‐rheumatic	  
treatment,	  of	  which	  24%	  had	  clinically	  evident	  disease	  (8%	  of	  all	  subjects)	   [51].	  A	  study	   in	  
patients	  with	  >10	   years	   from	  diagnosis	   of	  RA	   yielded	   similar	   results	   i.e.	   preclinical	   ILD	  on	  
HRCT	  in	  33%	  of	  the	  patients	  [52].	  Olson	  et	  al	  reported	  the	  prevalence	  of	  clinical	   ILD	  to	  be	  
about	  6.8%	  in	  women	  and	  9.8%	  in	  men	  [99].	  A	  study	  from	  Bongartz	  et	  al	  indicated	  a	  lifetime	  
risk	   of	   clinical	   ILD	   in	   RA	   to	   be	   approximately	   10%	   [56].	   ILD	   is	   usually	   considered	   a	  
complication	  of	  RA	  but	  in	  about	  10-­‐20%	  patients	  ILD	  predates	  RA	  [100-­‐102].	  
The	  clinical	  presentation	  of	  ILD	  is	  usually	  insidious	  with	  cough	  and	  progressive	  dyspnea	  on	  
exertion.	   Recognition	   may	   be	   delayed	   due	   to	   exercise	   limitations	   related	   to	   the	   joint	  
disease.	   Physical	   examination	   may	   reveal	   bibasilar	   crackles	   and	   clubbing	   in	   advanced	  
disease.	   Clinical	   evaluation	   includes	   laboratory	   testing,	   pulmonary	   function	   testing	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(restrictive	  pattern	  and	  impaired	  gas	  transfer	  for	  widespread	  disease),	  HRCT	  and	  in	  certain	  
cases	  bronchoalveolar	  lavage	  (BAL)	  and	  lung	  biopsy.	  	  
ILD	  is	  categorized	  according	  to	  the	  histopathological	  pattern	  that	  correlates	  quite	  well	  with	  
the	  radiographic	  appearance	  on	  HRCT	   [103].	  These	   include	  the	   following:	  usual	   interstitial	  
pneumonia	   (UIP),	   nonspecific	   interstitial	   pneumonia	   (NSIP),	   organizing	   pneumonia,	  
lymphocytic	   interstitial	   pneumonia,	   desquamative	   interstitial	   pneumonia	   and	   diffuse	  
alveolar	  damage	  [60].	  Usual	  interstitial	  pneumonia	  (UIP)	  is	  the	  predominant	  subtype	  in	  RA	  
and	  has	  been	  associated	  with	  a	  more	  severe	  outcome	  [101,	  104].	  
The	   diagnosis	   of	   the	   subtype	   is	   based	   on	   a	   combination	   of	   the	   clinical	   investigations	  
mentioned	  above.	  The	  use	  of	  HRCT	  in	  differentiating	  between	  subtypes	  and	  determining	  the	  
extent	   of	   disease	   is	   now	   well	   established	   [101].	   The	   typical	   HRCT	   changes	   for	   UIP	   are	  
traction	  bronchiectasis,	  honeycombing	  and	  reticular	  abnormalities,	  whereas	  in	  NSIP	  ground	  
glass	  opacification	  usually	  dominates	  and	  honeycombing	  is	  absent	  [57].	  A	  lung	  biopsy	  may	  
be	   required	   if	   a	   definite	   diagnosis	   cannot	   be	   determined,	   as	   this	   can	   be	   relevant	   for	  
treatment	   decisions.	   BAL	   is	   only	   needed	   in	   cases	   where	   other	   differential	   diagnoses	   are	  
suspected,	  e.g.	  infections,	  eosinophilic	  pneumonia	  or	  malignancy	  [105].	  	  
Risk	   factors	   for	   RA-­‐ILD	   have	   been	   reported	   to	   include	  male	   gender,	   high	   disease	   activity,	  
high	  autoantibody	  titers	  (RF	  and/or	  anti-­‐CCP)	  and	  smoking	  [101,	  106-­‐109].	  
1.2.3.1 Treatment	  of	  RA-­‐ILD	  and	  prognosis	  
Due	  to	  the	  lack	  of	  controlled	  trials	  the	  treatment	  recommendations	  are	  generally	  based	  on	  
treatment	   guidelines	   for	   idiopathic	   lung	   diseases,	   case	   series	   and	   expert	   opinions.	  When	  
taking	  decisions	  regarding	  treatment	  several	  factors	  need	  to	  be	  considered,	  such	  as	  subtype	  
of	  ILD	  and	  thereby	  the	  likelihood	  of	  response,	  extent	  of	  disease	  (>	  30%	  of	  lungs	  on	  HRCT),	  
severity	   and	   progression	   [110].	   Currently	   the	   management	   of	   subclinical	   RA-­‐ILD	   is	   not	  
recommended,	  as	  we	  lack	  knowledge	  on	  the	  natural	  history	  as	  well	  as	  treatment	  response	  
[111].	   Immunosuppressive	   treatment	   can	   be	   beneficial	   in	   RA-­‐ILD,	   with	   the	   exception	   of	  
patients	  with	  UIP.	  However,	  some	  studies	  have	  demonstrated	  a	  positive	  effect	  of	  treatment	  
in	  UIP,	   suggesting	   a	  better	   prognosis	   in	  RA-­‐UIP	   as	   compared	   to	   in	   idiopathic	   fibrosis	   or	   a	  
misdiagnosis	  of	  UIP	  instead	  of	  NSIP	  on	  HRCT	  [112].	  	  
Current	   therapy	   usually	   involves	   a	   combination	   of	   glucocorticoids	   and	   cytotoxic	   agents;	  
azathioprine,	  mycophenolate	  mofetil	  or	  cyclophosphamide	  [113,	  114].	  Methotrexate	  can	  be	  
considered	  after	  carefully	  considering	  the	  risk	  of	  lung	  toxicity	  [52].	  Case	  reports	  on	  the	  effect	  
of	   biological	   therapies	   (TNF	   inhibitors,	   rituximab,	   abatacept,	   tocilizumab)	   are	   conflicting,	  
with	   some	  reporting	  beneficial	  effect	   [115]	  and	  others	  a	  worsening	  of	   lung	  disease	   [116].	  
They	   should	   therefore	   be	   used	   with	   caution	   until	   more	   evidence	   for	   their	   use	   has	   been	  
published.	  
Given	  the	  causative	  role	  of	  smoking	   in	  both	  RA	  and	  ILD	  all	  patients	  should	  be	  encouraged	  
and	  supported	  to	  quit	  smoking.	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The	  prognosis	  for	  patients	  with	  RA-­‐ILD	  is	  poor,	  with	  a	  median	  survival	  after	  ILD	  diagnosis	  of	  
about	   3	   years	   [56,	   99,	   102].	  However,	   the	  prognosis	   varies	   somewhat,	   depending	  on	   the	  
underlying	  histopathological	  subtype.	  The	  poorest	  prognosis	  at	  five	  years	  was	  evident	  in	  the	  
group	  with	  diffuse	  alveolar	  damage	  (20%)	  and	  UIP	  (37%),	  whereas	  a	  better	  prognosis	  was	  
recorded	   for	   organizing	   pneumonia	   (60%)	   and	   NSIP	   (94%)	   [117].	   A	   study	   of	   prognostic	  
factors	  for	  progression	  of	  UIP	  found	  association	  with	  bibasilar	  crackles,	  low	  DLCO	  and	  extent	  
of	  HRCT	  changes	  on	  initial	  presentation.	  Using	  multivariate	  logistic	  regression,	  a	  DLCO	  below	  
54%	  remained	  the	  only	  significant	  predictor	  for	  progressive	  disease	  [118].	  
During	  recent	  years	  there	  have	  been	  speculations	  regarding	  the	  causal	   link	  between	  ACPA	  
and	  lung	  involvement.	  Studies	  have	  demonstrated	  associations	  between	  ACPA	  titers	  and	  the	  
presence	  of	  RA-­‐ILD	  and	  furthermore	  that	  lung	  changes	  can	  predate	  joint	  inflammation	  in	  a	  
proportion	  of	  patients	  [106,	  107,	  109,	  119,	  120].	  	  
In	  an	  effort	  to	  further	  understand	  the	  association	  between	  lungs	  and	  joints	  in	  RA,	  both	  from	  
a	  clinical	  and	  molecular	  viewpoint,	  we	   initiated	   the	  clinical	   study	  on	  LUng	   investigation	   in	  
newly	  diagnosed	  RA	  (LURA).	  
1.3 ETIOPATHOGENESIS	  OF	  RHEUMATOID	  ARTHRITIS	  
The	  cause	  of	  RA	  is	  unknown	  but	  much	  knowledge	  has	  been	  gained	  through	  research	  during	  
the	  last	  decades,	  and	  several	  etiopathogenic	  clues	  have	  now	  been	  identified.	  We	  do	  know	  
that	  RA	  is	  a	  complex	  disease	  in	  which	  interaction	  between	  genes	  and	  environmental	  factors	  
may	   induce	   immunological	   responses	   that	   generate	   autoimmunity,	   which	   subsequently	  
results	  in	  clinical	  disease	  in	  certain	  individuals.	  	  
The	   main	   focus	   here	   is	   to	   highlight	   possible	   etiologies	   and	   immunopathogenesis	   in	   RA	  
patients	   with	   emphasis	   on	   events	   prior	   to	   the	   appearance	   of	   clinical	   joint	   disease	   and	  
leading	  to	  development	  of	  autoimmunity.	  
1.3.1 	  	  	  	  Etiology	  
1.3.1.1 Genetics	  
We	  know	  from	  twin	  studies	  that	  genetic	  factors	  play	  an	  important	  role	  in	  the	  pathogenesis	  
of	  RA	  and	   it	  has	  been	  estimated	   that	  genetic	   susceptibility	  contributes	  about	  40-­‐60%	  to	  
the	  risk	  for	  RA	  [121,	  122].	  	  
The	   strongest	   genetic	   risk	   factor	   identified	   to	   date	   is	   genes	   coding	   regions	   within	   the	  
human	   leukocyte	   antigen	   (HLA)	   class	   II	   system	   (surface	   receptors	   expressed	   mainly	   on	  
antigen-­‐presenting	   cells),	   locus	   HLA-­‐DRB1.	   There	   are	   several	   HLA-­‐DRB1	   alleles	   (HLA-­‐
DRB1*0401,	   *0404,	   *01)	   that	   have	   been	   associated	  with	   RA	   and	   the	   products	   of	   these	  
alleles	  share	  a	  region	  of	  highly	  similar	  amino	  acid	  sequence	  at	  positions	  70-­‐74	  of	  the	  beta1	  
chain	  of	  HLA-­‐DRB1	  molecule,	   termed	   the	   shared	  epitope	   (SE).	   These	   residues	  belong	   to	  
the	   peptide-­‐binding	   (antigen)	   site	   and	   might	   therefore	   be	   implicated	   in	   antigen	  
presentation	  to	  CD4+	  T	  cells,	  suggesting	  its	  potential	  role	  in	  the	  pathogenesis	  of	  RA	  [123].	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Hill	  et	  al	  demonstrated	  that	  citrullinated	  peptides	  were	  more	  efficiently	  presented	  in	  the	  
context	   of	   HLA	   class	   II	   SE,	   contributing	   to	   enhanced	   T-­‐cell	   response	   [124].	   Notably,	   the	  
shared	  epitope	  only	  correlates	  with	  an	   increased	  risk	   for	  ACPA-­‐positive	  RA,	  but	  not	  with	  
ACPA-­‐negative	   RA	   [125,	   126].	   This	   relationship	   appears	   to	   be	   more	   important	   for	   the	  
progression	   from	  being	  ACPA-­‐positive	  healthy	   individual	   to	  developing	  ACPA-­‐positive	  RA	  
rather	   than	   for	   becoming	   ACPA-­‐positive	   [122].	   Furthermore,	   a	   study	   with	   20,000	  
individuals	   of	   European	   descent	   characterized	   additional	   amino	   acid	   sites	   within	   HLA-­‐
DRB1	  at	  positions	  11	  and	  13	  that	  are	  related	  to	  an	  increased	  risk	  for	  RA.	  These	  positions	  
are	   also	   within	   the	   DRB1	   binding	   groove	   (though	   not	   part	   of	   shared	   epitope)	   and	   are	  
involved	  in	  antigen	  binding	  [127].	  Investigators	  have	  estimated	  that	  HLA-­‐DR	  contributes	  to	  
less	  than	  50%	  of	  the	  genetic	  susceptibility	  in	  RA	  and	  vast	  numbers	  of	  other	  potential	  risk	  
genes	  have	  been	  suggested	  [128].	  	  	  
The	   second	   strongest	   genetic	   risk	   factor	   in	   RA	   appears	   to	   be	   the	   protein	   tyrosine	  
phosphatase,	  non-­‐receptor	   type	  22	   (PTPN22).	  PTPN22	   is	  expressed	   in	  both	  hematopoietic	  
tissue	   and	   cells	   of	   the	   immune	   system,	   and	   is	   thought	   to	   be	   involved	   in	   T-­‐	   and	   B-­‐cell	  
regulation	   [129].	   Several	   others	   risk	   alleles	   for	   RA	  have	   been	   identified	   through	   genome-­‐
wide	  studies,	  some	  of	  which	  also	  confer	  susceptibility	  to	  other	  autoimmune	  diseases.	  One	  
such	   polymorphism	   is	   for	   the	   peptidyl	   arginine	   deiminase	   type	   4	   (PADI4)	   gene,	   where	  
association	  was	  first	  demonstrated	  in	  the	  Asian	  population	  and	  subsequently	  in	  an	  European	  
Caucasian	  population	  [130-­‐132].	  	  
Although	   important	   knowledge	   regarding	   genes	   and	   their	   potential	   associations	   to	   RA	  
pathogenesis	  has	  been	  gained	  the	  last	  decades,	  much	  about	  RA	  heritability	  remains	  unclear.	  
1.3.1.2 Environmental	  factors	  
Airway	  exposures	  
The	  most	   established	   risk	   factor	   for	   RA	   is	   smoking	   [133,	   134]	   and	   studies	   have	   further	  
indicated	  an	  increased	  risk	  with	  higher	  intensity	  and	  duration	  of	  smoking	  [135,	  136].	  	  
However,	  the	  most	  striking	  findings	  are	  from	  studies	  investigating	  the	  interaction	  between	  
genetic	  and	  environmental	  risk	  factors,	  where	  smoking	  and	  the	  presence	  of	  two	  alleles	  of	  
the	   HLA-­‐DRB1	   shared	   epitope	   leads	   to	   an	   over	   20-­‐fold	   increased	   risk	   for	   developing	  
seropositive	  and	  in	  particular	  ACPA-­‐positive	  RA	  [125,	  126,	  137-­‐140].	  	  
Similar	  results	  have	  been	  reported	  regarding	  silica	  exposure	  and	  risk	  of	  ACPA-­‐positive	  RA	  
[141].	   In	   addition,	   other	   airway	   exposures,	   such	   as	   asbestos,	   aerosolized	   dust	   and	   air	  
pollution	  have	  been	   implicated	  as	   risk	   factors	   for	  RA	   [142-­‐144].	  Results	   from	  a	  study	  on	  
oral	  nicotine-­‐containing	  tobacco	  did	  not	  show	  any	  association	  with	  increased	  risk	  for	  RA,	  
suggesting	   that	   it	   is	   probably	   the	   irritants	   and	   not	   the	   nicotine	   that	   contribute	   to	   the	  
increased	  risk	  [145].	  
Infectious	  agents	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Infections	  have	  long	  been	  suspected	  to	  be	  a	  causative	  factor	  in	  RA	  and	  much	  research	  has	  
focused	  on	  attempting	  to	  define	  the	  responsible	  pathogenic	  virus	  or	  bacteria.	  Epstein	  Barr	  
virus,	   cytomegalovirus,	   retroviruses	  and	  human	  parvovirus	  B19	  have	  all	  been	  suspected,	  
but	  the	  current	  data	  are	  conflicting	  [146-­‐149].	  Regarding	  bacterial	  infections,	  some	  studies	  
have	   indicated	   an	   association	   with	   serological	   findings	   of	   Proteus	   mirabilis	   and	  
Mycoplasma	   species	   and	   an	   increased	   risk	   for	   RA	   [150-­‐152].	   However,	   a	   recently	  
published	  large	  population-­‐based	  case-­‐control	  study	  determined	  no	  association	  between	  
prior	   infections	   in	   respiratory-­‐gastrointestinal-­‐	   or	   urogenital	   tracts	   and	   an	   increased	   RA	  
risk	  [153].	  
Several	   studies	   have	   reported	   an	   association	   between	   RA	   and	   periodontal	   disease,	   in	  
which	   the	   major	   etiologic	   agent	   is	   the	   Porphyromonas	   gingivalis	   bacterium.	   This	  
bacterium	  contains	  the	  enzyme	  peptidyl	  arginine	  deiminase	  (PAD)	  which	  may	  lead	  to	  the	  
generation	   of	   intrinsic	   citrullinated	   proteins	   or	   potentially	   induces	   citrullination	   of	   host	  
proteins.	   Either	   way	   this	   could	   lead	   to	   the	   first	   breaking	   of	   immune	   tolerance,	   and	   in	  
genetically	   susceptible	   individuals	   (e.g.	   HLA-­‐DR	   SE)	   the	   evocation	   of	   immune	   reactivity	  
with	   subsequent	   antibody	   production	   (ACPAs)	   [154-­‐157].	   Another	   potential	   mechanism	  
may	  be	   that	   antibodies	   are	   initially	   produced	   against	   the	  bacterial	   citrullinated	  proteins	  
and	   through	   molecular	   mimicry	   lead	   to	   the	   breaking	   of	   immune	   tolerance.	   Further	  
support	   comes	   from	   a	   study	   of	   RA	   patients	   and	   their	   non-­‐RA	   relatives,	   revealing	   an	  
association	   between	   antibodies	   against	   Porphyromonas	   gingivalis	   and	   the	   presence	   of	  
ACPA	  in	  genetically	  susceptible	  patients	  and	  at-­‐risk	  individuals	  [158].	  	  
The	  gut	  microbiome	  contains,	  as	  the	  name	  implies,	  commensal,	  symbiotic	  and	  pathogenic	  
microorganisms	  [159].	  They	  usually	  live	  in	  harmony	  but	  the	  equilibrium	  can	  be	  disrupted	  
due	   to	   external	   factors	   such	   as	   infections,	   diet	   and	   antibiotic	   use,	   leading	   to	   diseases.	  
Further,	  the	  gut	  microbiome	  is	  believed	  to	  influence	  the	  development	  of	  both	  the	  innate	  
and	   adaptive	   immune	   systems	   and	   has	   been	   implicated	   in	   the	   pathogenesis	   of	  
autoimmune	  diseases	  [160-­‐162].	  Several	  studies	  have	  demonstrated	  differences	  in	  the	  gut	  
microbiome	   between	   RA	   patients	   and	   controls	   [163,	   164].	   The	   study	   from	   Scher	   et	   al	  
found	  more	  Prevotella	  copri	   in	  untreated	  new-­‐onset	  RA	  patients	  compared	  with	  chronic,	  
treated	  RA	  patients	   [164]	  and	  Liu	  et	  al	   reported	  a	  greater	  abundance	  of	  Lactobacillus	   in	  
DMARD	   naïve,	   early	   RA	   patients	   compared	   to	   in	   healthy	   controls	   [163].	   However,	   the	  
implications	  of	  these	  studies	  are	  only	  tentative.	  Larger	  studies	  are	  needed	  to	  fully	  evaluate	  
the	  microbiome	  in	  both	  gut	  and	  other	  mucosal	  surfaces	  in	  RA	  patients.	  	  	  
Other	  risk	  factors	  
Given	   the	   unequal	   gender	   distribution	   hormonal	   factors	   probably	   play	   a	   role	   in	   the	  
pathogenesis	  of	  RA.	  Additional	  support	  is	  the	  higher	  peak	  of	  RA	  incidence	  postpartum	  and	  
subsequent	   to	   menopause	   when	   hormonal	   levels	   fluctuate.	   Studies	   regarding	   the	  
protective	   role	   of	   oral	   contraceptives	   against	   RA	   have	   been	   conflicting	   [165-­‐167].	  	  
Recent	  studies	  have	  also	  shown	  an	  association	  between	  obesity	  and	  an	   increased	  risk	  of	  
developing	   RA	   [168,	   169].	   Lu	   et	   al	   observed	   an	   association	   between	   obesity	   and	   both	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seropositive	  and	  negative	  RA	  in	  women	  while	  Wesley	  et	  al	  only	  determined	  an	  association	  
with	  seronegative	  RA	  in	  women	  [170].	  Other	  environmental	  factors,	  such	  as	  the	  potential	  
protective	  role	  of	  dietary	  factors	  and	  alcohol	  on	  the	  risk	  of	  RA	  are	  inconclusive	  and	  need	  
to	  be	  studied	  further	  [167].	  	  	  
1.3.2 	  	  	  	  Immunopathogenesis	  
It	  is	  known	  that	  RA	  is	  caused	  by	  a	  complex	  interaction	  between	  genes	  and	  the	  environment,	  
leading	  to	  a	  breaking	  of	   immune	  tolerance	  with	  consecutive	  generation	  of	  autoantibodies	  
such	  as	  RF	  and/or	  ACPA.	   Interestingly,	  ACPAs,	  RF	  and/or	  antibodies	  against	   carbamylated	  
proteins	   can	   be	   detected	   in	   blood	   many	   years	   prior	   to	   the	   appearance	   of	   the	   articular	  
disease	   [20-­‐23]	   suggesting	   that	   autoimmunity	   develops	   years	   before	   disease	   onset.	   This	  
gives	  us	  unique	  opportunities	   to	  not	  only	   investigate	   the	   longitudinal	  development	  of	  RA,	  
but	   also	   to	   potentially	   interfere	   with	   this	   development	   in	   order	   to	   prevent	   joint	  
inflammation.	   Importantly,	   a	   proportion	   of	   ACPA-­‐positive	   healthy	   individuals	  might	   never	  
develop	   joint	   inflammation	  or	  RA	  [122,	  171,	  172]	  and	  we	  need	  to	   identify	   the	  differences	  
between	   these	   groups.	   A	   first	   step	   is	   to	   gain	   knowledge	   on	   how	   and	  why	   autoimmunity	  
occurs	  and	  secondly	  identify	  the	  factors	  that	  determine	  which	  individuals	  will	  progress	  and	  
develop	  joint	  inflammation,	  while	  others	  will	  remain	  healthy.	  	  
The	  following	  sections	  will	  explain	  the	  citrullination-­‐	  and	  carbamylation	  processes	  and	  the	  
immune	  responses	  evoked	  against	  these	  modifications.	  
1.3.2.1 Post-­‐translational	  modifications	  
Citrullination	   is	  a	  post-­‐translational	  modification,	  during	  which	  the	  positive	  charged	  amino	  
acid	  arginine	  is	  deiminated	  to	  the	  neutral	  amino	  acid	  citrulline.	  This	  process	  is	  catalyzed	  by	  
enzymes	   called	   peptidyl	   arginine	   deiminases	   (PADs),	   whose	   activities	   are	   dependent	   on	  
higher	  levels	  of	  calcium	  (Ca2+)	  than	  normally	  occur	  in	  living	  cells	  [173].	  Five	  isoforms	  of	  PAD	  
have	  been	  identified,	  but	  PAD2	  and	  PAD4	  are	  particularly	  relevant	  to	  RA	  as	  these	  have	  been	  
demonstrated	  in	  the	  inflamed	  synovium	  of	  RA	  patients	  [174,	  175]	  and	  are	  active	  in	  myeloid	  
cells	   [176,	   177].	   Citrullination	   is	   a	   normal	   physiological	   process	   that	   associates	   with	  
inflammation	   [178]	   and	   supposedly	   takes	   place	   both	   intra-­‐	   and	   extracellularly.	   Given	   the	  
required	  high	  levels	  of	  Ca2+	  for	  PAD	  activation	  it	  has	  been	  suggested	  that	  cell	  death	  in	  the	  
context	  of	   infections	  or	   inflammation	  will	  allow	  extracellular	   leakage	  of	  PAD	  enzymes	  and	  
high	  Ca2+	  levels,	  leading	  to	  extracellular	  citrullination	  [179].	  However,	  this	  is	  not	  completely	  
true	   in	   the	   case	   of	   joint	   inflammation	   in	   which	   only	   very	   low	   levels	   of	   cell	   death	   occur	  
despite	  inflammation.	  Possibly	  other	  redundant	  in	  vivo	  mechanisms	  regulating	  PAD	  activity	  
even	  at	   lower	  Ca2+	  levels	  exist,	  and	   these	  still	  need	   to	  be	  characterized.	   Interestingly,	  one	  
recent	   study	   demonstrated	   that	   antibodies	   that	   cross-­‐react	   with	   PAD3	   and	   PAD4	   can	  
contribute	  to	  an	  enhanced	  citrullinating	  capacity	  of	  PAD4	  by	  lowering	  the	  threshold	  for	  Ca2+	  
required	   for	   activation	   [180].	   Citrullination	   of	   proteins	   induces	   structural	   and	   polarity	  
changes	  that	  might	  eventually	  uncover	  new	  antigens	  or	  neoepitopes.	  Citrullination	  may	  thus	  
render	   the	  protein	   ‘foreign’	  and	  possibly	  antigenic,	  but	   it	   is	  only	   in	   the	  context	  of	  genetic	  
susceptibility	  that	  immune	  reactivity	  against	  these	  proteins	  occurs	  [181].	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Carbamylation	   is	   another	   post-­‐translational	   modification	   relatively	   recently	   linked	   to	   RA	  
pathogenesis,	  where	  lysine	  is	  converted	  into	  homocitrulline	  through	  a	  chemical	  reaction	  by	  
cyanate.	   Cyanate	   is	   naturally	   present	   in	   the	   body.	   Smoking	   enhances	   carbamylation	   by	  
increasing	   the	   cyanate	   concentration	   [182].	   Carbamylation,	   as	   with	   citrullination,	   is	  
predominantly	  believed	   to	  occur	  during	   inflammation	   [183].	  Anti-­‐carbamylated	  antibodies	  
can	  be	  found	  in	  ACPA-­‐positive	  RA	  and	  also	  in	  about	  15%	  of	  ACPA-­‐negative	  RA	  patients	  [19,	  
184].	  
1.3.2.2 Antibodies	  against	  post-­‐translational	  modifications	  
Even	  though	  citrullination	  and	  carbamylation	  appear	  to	  be	  ubiquitous	  processes	  that	  are	  not	  
unique	  to	  RA,	  the	  immune	  responses	  evoked	  by	  these	  modified	  proteins	  are	  highly	  specific	  
for	  RA	  and	  are	  not	  evident	  in	  other	  inflammatory	  diseases	  [14,	  19].	  
The	  ACPA	  response	   is	  very	  heterogeneous	  and	  contains	  a	  repertoire	  of	  diverse	  antibodies	  
with	  fine	  specificities	  against	  different	  citrullinated	  epitopes	  of	  different	  proteins.	  This	  pool	  
of	  antibodies	  differs	  between	  individual	  patients	  and	  they	  can	  be	  partly	  cross-­‐reactive	  [14,	  
16,	   185,	   186].	   Studies	   have	   demonstrated	   antibody	   reactivities	   against	   citrullinated	  
extracellular	  and/or	  cell	  surface	  bound	  targets,	  such	  as	  collagen	  II,	  vimentin,	  alpha-­‐enolase	  
and	  fibrinogen,	  which	  have	  all	  been	  localized	  in	  inflamed	  joints	  in	  RA	  [16,	  156,	  187-­‐190].	  In	  
addition,	   ACPAs	   directed	   against	   intracellular	   molecules	   such	   as	   histones	   have	   been	  
identified	   [191].	   Recent	   studies	   have	   demonstrated	   a	   breaking	   of	   tolerance	   to	   one	  
citrullinated	   epitope	   initially,	   with	   subsequent	   gradual	   epitope	   spreading	   and	   increasing	  
reactivities,	  such	  that	  the	  ACPA	  response	  becomes	  more	  diverse	  and	  the	  levels	  of	  antibodies	  
higher	  [189,	  190,	  192].	  This	  initial	  breaking	  of	  tolerance	  seems	  to	  differ	  between	  individuals,	  
but	   no	   causative	   associations	   have	   yet	   been	   reported.	   Shortly	   before	   onset	   of	   clinical	  
symptoms	  there	  is	  a	  rather	  rapid	  rise	  in	  diversity	  and	  titers	  of	  ACPAs	  and	  certain	  patterns	  of	  
reactivities	  emerge,	  suggesting	  that	  certain	  combinations	  of	  antibodies	  may	  be	  more	  likely	  
to	  induce	  arthritis	  [190].	  Moreover,	  the	  ACPAs	  diverse	  immune	  response	  is	  fully	  developed	  
at	   the	   onset	   of	   articular	   disease	   and	   very	   few	   individuals	   become	   ACPA-­‐positive	   at	   later	  
stages	   of	   the	   disease	   course	   [27,	   181,	   185].	   Parallel	   to	   the	   rise	   and	   diversity	   of	  
autoantibodies	   an	   increase	   in	   cytokine	   and	   chemokine	   levels	   occurs,	   probably	   reflecting	  
activation	   of	   adaptive	   immunity	   and	   the	   presence	   of	   systemic	   pre-­‐clinical	   inflammation	  
[189,	  193].	  	  
The	   increasing	   knowledge	   of	   the	   possible	   associations	   of	   different	   ACPA	   specificities	   to	  
different	   clinical	  manifestations	   and	   their	   relation	   to	   risk	   factors	   is	   of	   particular	   interest.	  
Associations	  with	  antibodies	  against	  cit-­‐vimentin	  and	  cit-­‐alpha	  enolase	  and	  smoking	  in	  the	  
presence	   of	   certain	   HLA-­‐DRB1	   SE	   alleles	   and	   PTPN22	   have	   been	   reported	   [155,	   194].	   As	  
previously	  mentioned,	   antibodies	   against	   cit-­‐vimentin	   have	   also	   been	   strongly	   associated	  
with	  severe	  ExRA	  [49].	  
  16 
1.3.2.3 Potential	  role	  of	  ACPAs	  
Besides	  the	  role	  of	  ACPAs	  in	  diagnosis	  of	  RA	  they	  may	  also	  contribute	  to	  important	  
pathophysiologic	  processes	  in	  RA:	  
1. ACPAs	  are	  detectable	  in	  the	  blood	  years	  before	  symptoms	  of	  joint	  inflammation	  and	  
predict	   development	   of	   RA	   in	   patients	  with	   undifferentiated	   arthritis	   or	   arthralgia	  
[21,	  22,	  195].	  
2. ACPAs	  associate	  with	  higher	  disease	  activity	   and	   joint	  destruction	  as	   compared	   to	  
ACPA-­‐negative	  patients	  [25,	  27].	  
3. RA	  patients	  have	  a	  sustained	  production	  of	  IgM	  ACPA	  [196].	  
4. Animal	  studies	  have	  demonstrated	  that	  ACPAs,	  while	  not	  able	  to	  induce	  arthritis	  by	  
themselves,	  worsen	  disease	  course	  in	  susceptible	  mice	  [197].	  
Pathogenic	  effect	  of	  ACPAs	  in	  joints	  of	  RA	  patients	  
Higher	   titers	  of	  ACPAs	   in	   synovial	   fluids	   than	   in	   serum	   indicate	   that	  ACPAs	  are	  generated	  
within	   the	   joint	   during	   established	   disease	   [198]	   and	   the	   ultimate	   proof	   came	   from	   the	  
demonstration	  that	  B	  cells	  from	  inflamed	  joints	  of	  RA	  patients	  produce	  ACPAs.	  Furthermore,	  
these	   authors	   determined	   that	   these	   antibodies	   had	   undergone	   multiple	   mutations	   and	  
thus	  probably	  received	  help	   from	  T	  cells	   [186].	  Less	   is	  known	  about	  the	  T	  cell	   reactivities,	  
although	   some	   studies	   have	   reported	   reactivities	   against	   collagen	   type	   II	   [199],	   cit-­‐
fibrinogen	  [200]	  and	  cit-­‐vimentin	  [201].	  
ACPA	   bound	   to	   its	   cit-­‐protein	   (antigen)	   can	   form	   immune	   complexes,	   and	   immune	  
complexes	  have	  been	  shown	   in	  animal	  models	   to	  be	  central	  players	   in	  mediating	  synovial	  
inflammation	  [202].	  These	  immune	  complexes	  can	  activate	  macrophages	  and	  other	  immune	  
cells	   through	   toll-­‐like	   receptors	   and	   Fcγ	   receptors,	   thereby	  mediating	  effects	   such	  as	   TNF	  
alpha	  production	  and	  activation	  of	  the	  complement	  system	  (Figure	  2)	  [203-­‐205].	  	  
Antibodies	   against	   cit-­‐vimentin	   promote	   release	   of	   neutrophil-­‐derived	   extracellular	   traps	  
(NET:s),	  which	  are	  thereby	  able	  to	  activate	  macrophages	  [206].	  Additionally,	  ACPAs	  can	  bind	  
cit-­‐proteins	  present	  in	  NET:s	  and	  consequently	  activate	  fibroblasts	  [205,	  207].	  	  
Interestingly,	   Harre	   et	   al	   recently	   reported	   that	   antibodies	   to	   cit-­‐vimentin	   are	   able	   to	  
contribute	  to	  activation	  of	  osteoclasts	  [208],	  which	  may	  account,	  at	  least	  partly,	  for	  the	  joint	  
erosions	   and	   could	   possibly	   contribute	   to	   the	   initiation	   of	   joint	   inflammation.	   We	   have	  
recently	  described	  in	  our	   laboratory	  that	  both	  polyclonal	  affinity	  purified	  ACPAs	  as	  well	  as	  
certain	  monoclonal	  ACPAs	  are	  able	  to	  directly	  interact	  with	  targets	  on	  the	  osteocyte	  surface	  
to	   induce	   an	   intracellular	   activation	   resulting	   in	   secretion	   of	   IL-­‐8	   that	   further	   increases	  
osteocyte	  activation	  in	  an	  autocrine	  manner	  (Krishnamurthy	  et	  al,	  Annals	  of	  the	  Rheumatic	  
Diseases,	  in	  press).	  	  
Altogether	   this	   leads	   not	   only	   to	   increased	   production	   of	   immune	   mediators	   and	  
inflammation	   but	   may	   also	   add	   to	   the	   generation	   of	   more	   cit-­‐proteins	   and	   increased	  
immune	  responses,	  so-­‐called	  epitope	  spreading.	  Following	  increased	  production	  of	  immune	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complexes	   (ACPAs	   bound	   to	   cit-­‐protein),	   RF	   may	   subsequently	   be	   produced	   given	   their	  
probable	  role	  in	  complement	  activation	  [192,	  209,	  210].	  
ACPAs	  are	  generated	  within	  the	  joint	  during	  established	  disease	  but	  probably	  not	  during	  the	  
pre-­‐clinical	  period	  as	  studies	  have	  not	  found	  any	  signs	  of	  inflammation	  or	  immune	  activation	  
in	  the	  joint	  prior	  to	  joint	   inflammation	  [211].	  Since	  ACPAs	  are	  present	   in	  the	  blood	  before	  
onset	  of	  disease,	  then	  where	  do	  ACPAs	  originate	  from	  and	  how	  may	  the	  immune	  tolerance	  
to	  citrullinated	  proteins	  be	  broken?	  	  
1.3.2.4 Potential	  origin	  of	  ACPAs	  	  
Most	   of	   the	   environmental	   risk	   factors	   mentioned	   above	   originate	   at	   mucosal	   surfaces.	  
Furthermore,	  one	  study	   reported	   that	   the	  proportion	  of	   IgA	  ACPA	  was	  higher	   than	   IgG	   in	  
individuals	  at	  risk	  for	  RA	  [212].	  Other	  studies	  have	  demonstrated	  the	  presence	  of	  IgA	  ACPA	  
early	   in	   the	   disease	   course	   and	   in	   addition	   found	   associations	   with	   smoking	   [213,	   214].	  
Altogether,	   this	   suggests	   that	   the	   production	   of	   ACPA	   might	   originate	   from	   mucosal	  
surfaces.	  As	  smoking	  is	  the	  best	  established	  risk	  factor	  for	  ACPA-­‐positive	  RA,	  and	  bearing	  in	  
mind	  that	  RA	  patients	  often	  have	  lung	  changes,	  the	  lung	  could	  be	  a	  potential	  initiating	  site	  in	  
a	  subset	  of	  patients.	  	  
Lung	  immunity	  
The	  lungs	  are	  in	  immediate	  contact	  with	  the	  outside	  environment	  through	  the	  upper	  and	  
lower	   airways	   and	   are	   thereby	   exposed	   to	   various	   stimuli,	   irritants	   and	   infections.	   They	  
are	  equipped	  with	  different	  defense	  mechanisms.	  The	  epithelium	  lining	  the	  bronchial	  tree	  
contains	  ciliated	  epithelial	  cells	  and	  mucus-­‐producing	  goblet	  cells.	  On	  the	  luminal	  surface	  
there	  are	   immunoglobulins,	  complement	  proteins,	  cells	  of	  the	   innate	  (e.g.	  macrophages,	  
dendritic	   cells	   and	   neutrophils)	   and	   adaptive	   immune	   systems	   (T-­‐	   and	   B-­‐cells)	   [215].	  
Alveolar	  macrophages	   are	   the	  most	   abundant	   cells	   in	   airways	   of	   healthy	   lungs	   and	   are	  
essential	  for	  its	  non-­‐specific	  defense.	  Besides	  the	  macrophages	  role	  in	  phagocytosis,	  they	  
are	  able	  to	  recruit	  other	  cells	  of	  the	  immune	  system,	  secrete	  pro-­‐inflammatory	  mediators	  
and	   act	   as	   antigen	   presenting	   cells	   [216].	   In	   the	   lung	   ectopic	   lymphatic	   tissue	   called	  
bronchus-­‐associated	  lymphoid	  tissue	  can	  form	  in	  response	  to	  inflammation	  or	  infections.	  
This	   allows	   for	   local	   production	   of	   antibodies	   in	   the	   lung	   and	   class	   switching,	   thereby	  
efficiently	   eliminating	   the	   pathogen	   [217,	   218].	   Thus	   the	   lungs	   are	   exposed	   to	   various	  
stimuli	   and	   have	   an	   efficient	   immune	   system	   and	   the	   potential	   to	   generate	   antibodies	  
locally.	   The	   lung	   also	   has	   a	   microbiome	   in	   which	   subtle	   changes	   may	   contribute	   to	  
initiation	  of	  autoimmunity.	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Possible	  mechanisms	  underlying	  initiation	  of	  autoimmunity	  and	  generation	  of	  antibodies	  
The	  innate	  immune	  system	  recognizes	  agents	  via	  pattern	  recognition	  receptors.	  Their	  role	  is	  
to	  eliminate	  potential	  pathogens,	   recruit	   immune	  cells	  and	  activate	   the	  adaptive	   immune	  
system	   [219].	   Below	   follows	   a	   description	   of	   potential	   steps	   in	   activation	   of	   innate	   and	  
adaptive	   immunity,	  ultimately	   leading	  to	  the	  generation	  of	  antibodies	  against	  citrullinated	  
proteins.	  Smoking	  will	  be	  used	  as	  an	  example	  of	  a	  risk	  factor.	  	  
Step	  1.	  Repeated	  stimuli	  from	  irritants	  such	  as	  smoking	  (or	  infections)	  can	  lead	  to	  activation	  
of	   the	   innate	   immune	  system.	  This	   can	  occur	  by	   several	  mechanisms,	   for	  example	   smoke	  
activation	  of	  dendritic	  cells,	  macrophages	  and	  other	  cells	  of	  the	   innate	  system	  via	  pattern	  
recognition	  molecules	  [220].	  Smoking	  can	  also	  induce	  alveolar	  macrophage	  apoptosis	  [221].	  
In	   addition,	   smoke	   enhances	   bacterial	   colonization	   of	   the	   lungs	   and	   alters	   the	   balanced	  
microbiome,	   which	   can	   activate	   the	   innate	   system	   and	   in	   case	   of	   infections,	   adaptive	  
immunity	  [222].	  
Step	  2.	  Increased	  activation	  of	  the	  innate	  system	  and	  increased	  cell	  death	  may	  exceed	  the	  
phagocytic	  capacity	  of	  phagocytes.	  PAD	  enzymes	  and	  citrullinated	  proteins	  can	  leak	  out	  into	  
the	  extracellular	  space,	  leading	  to	  increased	  extracellular	  citrullination	  and	  rendering	  them	  
visible	  to	  the	  immune	  system.	  
Step	  3.	  The	  antigen	  presenting	  cells	  (dendritic	  cell,	  macrophages,	  B-­‐cells)	  (now	  activated	  by	  
smoke)	   present	   the	   citrullinated	   antigen	   bound	   to	   HLA	   class	   II	  molecule	   to	   CD4+	   T	   cells.	  
Usually	  does	  this	  antigen	  presentation	  not	  lead	  to	  immune	  reactivity.	  However,	  individuals	  
that	   possess	   the	   susceptible	   genes,	   such	   as	   shared	   epitope,	  may	   bind	   those	   citrullinated	  
antigens	  more	  efficiently,	   contributing	   to	  enhanced	  T	   cell	   activation	   [124].	   T	   cells	  present	  
these	   antigens	   to	   B	   cells,	  which	   in	   the	   presence	   of	   additional	   co-­‐stimulatory	   factors	  may	  
differentiate	  into	  plasma	  cells	  and	  generate	  antibodies	  (ACPA).	  
Step	  4.	  After	  the	  first	  breaking	  of	  tolerance	  with	  antibody	  generation	  a	  following	  cascade	  of	  
events	  may	  occur:	  ACPA	  bound	  to	  citrullinated	  protein	  can	  form	  immune	  complexes,	  which	  
can	   further	   activate	   innate	   immune	   cells	   through	   toll-­‐like	   receptors	   as	   well	   as	   the	  
complement	   system	   through	   Fcγ	   receptors	   [205].	   This	   (in	   combination	   with	   the	   original	  
stimuli)	  contributes	  to	  increased	  activation	  of	  immune	  cells,	  more	  inflammation,	  increased	  
citrullination	  and	   formation	  of	  more	   immune	  complexes.	  A	  vicious	  cycle	  occurs	  and	   if	   the	  
immune	  system	  cannot	  control	  this,	  perhaps	  due	  to	  some	  defect	  in	  regulatory	  T-­‐cells	  and	  in	  
the	  presence	  of	  continuous	  stimulation,	  this	   leads	  to	  epitope	  spreading	  and	  diversification	  
of	  the	  ACPA	  response.	  	  	  
The	   lungs	   are	   thus	   immunologically	   active	   organ	   and	   exposed	   to	   various	   stimuli.	   The	  
knowledge	  that	  lung	  manifestations	  can	  appear	  before	  joint	  inflammation	  [56,	  62,	  76]	  and	  
an	  association	  has	  been	  found	  between	  the	  presence	  of	  ACPA	  and	  interstitial	   lung	  disease	  
even	   in	   the	   absence	   of	   joint	   inflammation	   further	   strengthen	   this	   relationship	   [119].	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Moreover,	  Rangel-­‐Moreno	  et	  al	  found	  ectopic	  lymphoid	  tissue	  in	  the	  lungs	  of	  patients	  with	  
longstanding	   RA	   and	   concomitant	   lung	   disease	   and	   B	   cells	   which	   were	   able	   to	   bind	  
citrullinated	  proteins,	  indicating	  a	  local	  antibody	  production	  in	  the	  lungs	  [223].	  
Many	  other	  questions	  about	  the	  involvement	  and	  the	  role	  of	  the	  lungs	  in	  early	  RA	  are	  still	  not	  
addressed	  and	  in	  the	  current	  studies	  I	  have	  explored	  part	  of	  these	  questions.	  My	  focus	  has	  
been	   on	   the	   extent	   of	   lung	   involvement,	   and	   whether	   there	   are	   any	   signs	   of	   immune	  
activation	   in	  the	   lungs	  of	  early	  RA	  patients.	  The	  results	  will	  be	  presented	  and	  discussed	   in	  
the	  next	  chapters.	  
Given	   that	  autoimmunity	   is	   generated	  outside	   the	   joint	  we	  miss	  a	  potential	   link	  between	  
presence	  of	  ACPA	  in	  serum	  and	  inflammation	  in	  joints,	  that	  is	  the	  transition	  from	  a	  healthy	  
ACPA-­‐positive	   individual	   to	   a	   patient	  with	   ACPA-­‐positive	   joint	   inflammation.	   Speculations	  
have	  been	  about	  a	  minor	  trauma	  or	   infection	  that	  could	   lead	  to	   inflammation	   in	  the	   joint	  
and	   thereby	   induce	   citrullination	   of	   proteins	   [178,	   181].	   Usually	   this	   would	   go	   by	  
unrecognized,	  but	  perhaps	  as	   the	  ACPAs	  are	  already	  available	   these	   citrullinated	  proteins	  
could	   attract	   antibodies	   into	   the	   joint,	   and	  with	   the	   right	   combination	   these	  may	   induce	  
generation	  of	  immune	  complexes,	  inflammation,	  recruitment	  of	  cells	  of	  the	  immune	  system,	  
angiogenesis,	  which	  ultimately	  leads	  to	  joint	  inflammation	  and	  onset	  of	  clinical	  disease.	  	  
For	  this	  to	  occur	  the	  same	  targets	  must	  be	  present	  in	  the	  joints	  and	  in	  the	  potential	  initiating	  
organ	  (this	  issue	  has	  been	  addressed	  in	  the	  current	  thesis,	  Paper	  III).	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Figure	   2.	   A	   schematic	   presentation	   of	   the	   lung-­‐joint	   hypothesis	   and	   potential	   effector	  
mechanisms	  of	  ACPAs	  in	  joint.	  
	  
	  
Adapted	  from	  Catrina	  et	  al	  [224].	  ACPAs	  =	  anti-­‐citrullinated	  protein	  antibodies,	  APC	  =	  antigen	  presenting	  cells,	  
BAL	  =	  bronchoalveolar	  lavage.	  
Smoking,	  silica	  and	  other	  possible	  irritants	  can	  lead	  to	  activation	  of	  the	  innate	  immune	  system	  and	  increased	  
expression	  of	  citrullinated	  proteins.	  In	  genetically	  susceptible	  individuals	  these	  cit-­‐proteins	  when	  presented	  by	  
APC	  lead	  to	  activation	  of	  T-­‐cells,	  which	  may	  thereby	  induce	  maturation	  of	  B-­‐cells	  and	  subsequently	  production	  
of	   antibodies.	   Initially	   only	   one	   specificity	   of	   ACPA	   is	   produced	   but	  with	   subsequent	   epitope	   spreading	   the	  
diversity	  and	  titers	  of	  ACPA	  increase.	  	  
ACPA	   may	   exert	   its	   pathogenic	   effect	   by	   forming	   immune	   complexes	   that	   can	   activate	   macrophages,	  
neutrophils	   (leading	   to	  NET:osis),	  and	  the	  complement	  system	  through	  toll-­‐like	  and	  Fcγ	   receptors.	  ACPA	  can	  
further	  activate	  osteoclasts.	  B-­‐cells	  are	  found	  in	  joints	  that	  produce	  ACPAs.	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2 AIMS	  
The	  overall	  aim	  of	   this	   thesis	  was	   to	  characterize	   the	   temporal	   relationship	  between	   lung	  
manifestations	  and	  joint	  disease	  onset	  and	  to	  investigate	  whether	  autoimmunity	  in	  RA	  may	  
be	  generated	  in	  the	  lungs.	  	  
The	  specific	  aims	  were:	  
i)	   to	   characterize	   lung	   involvement	   in	   early	   RA	   patients	   and	   to	   compare	   it	   to	   healthy	  
individuals.	  	  
ii)	  to	  characterize	  expression	  of	  citrullinated	  proteins	  as	  well	  as	  the	  degree	  of	  inflammation	  
and	  immune	  activation	  in	  BAL	  and	  bronchial	  tissue	  of	  patients	  with	  early	  RA.	  	  
iii)	   to	   study	   the	   link	   between	   the	   lungs	   and	   joints	   in	   RA	   patients	   by	   assessing	   shared	  
immunological	  targets	  in	  these	  organs.	  
iv)	  to	  characterize	  the	  clinical	  and	  immunological	  lung	  response	  to	  anti-­‐rheumatic	  treatment	  
in	  RA	  patients.	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3 PATIENTS	  AND	  METHODS	  
3.1 SUBJECTS	  
The	   studies	   presented	   in	   this	   thesis	   were	   approved	   by	   the	   local	   ethics	   committee	   in	  
Stockholm.	  Written	  informed	  consent	  was	  obtained	  from	  all	  patients	  and	  controls.	  	  
LURA	   cohort:	   All	   the	   studies	   presented	   in	   this	   thesis	   are	   based	   on	   data	   from	   the	   LUng	  
investigation	  in	  newly	  diagnosed	  RA	  patients	  (LURA)	  cohort.	  
These	  patients	  were	  recruited	  at	  the	  early	  arthritis	  clinic	  at	  Karolinska	  University	  Hospital	  in	  
Solna	  and	  Huddinge	  between	  2007	  and	  2012.	  Individuals	  with	  new	  onset	  of	  joint	  pain	  were	  
referred	  from	  primary	  care	  centers	  in	  the	  Stockholm	  area	  to	  the	  arthritis	  clinic	  at	  Karolinska.	  
Those	  that	  fulfilled	  the	  ACR	  criteria	  from	  1987	  and	  had	  a	  symptom	  duration	  of	  less	  than	  a	  
year	  were	  invited	  to	  participate	  in	  the	  study.	  Exclusion	  criteria	  were	  previous	  treatment	  with	  
disease-­‐modifying	  anti-­‐rheumatic	  treatment	  and/or	  oral	  glucocorticoids,	  pregnancy	  or	  plans	  
for	  pregnancy,	  severe	  debilitating	  disease,	  alcohol	  and/or	  drug	  abuse.	  All	  included	  patients	  
were	   investigated	   according	   to	   the	   clinical	   routine	   at	   the	   arthritis	   clinic	   at	   Karolinska.	  
Thorough	  clinical	  examination	  was	  conducted,	  joint	  assessment,	  DAS28,	  conventional	  blood	  
samples	   and	   X-­‐ray	   of	   the	   lungs,	   hands	   and	   feet	   taken.	   Participating	   in	   the	   study	   also	  
included	   the	   following	   investigations:	   high	   resolution	   computed	   tomography	   (HRCT),	  
dynamic	   spirometry,	   body	   plethysmography	   and	   measurement	   of	   diffusing	   capacity	   for	  
carbon	   monoxide	   (DLCO),	   research	   blood	   samples	   and	   answering	   questionnaires	   about	  
respiratory	  symptoms	  and	  previous	  history	  of	  pulmonary	  diseases.	  We	   included	  a	   total	  of	  
143	  patients,	  of	  which	  105	  patients	  underwent	  HRCT	  (not	  included	  in	  the	  protocol	  from	  the	  
beginning).	   Patients	   were	   followed	   prospectively	   and	   the	   same	   investigations	   were	  
repeated	  after	   six	  months	  of	   treatment.	   Information	  on	  demographic	  characteristics	   from	  
the	  EIRA	  study	  (a	   large	  population-­‐based	  epidemiological	   investigation	  in	  newly	  diagnosed	  
RA	  patients)	  is	  included	  in	  Table	  4	  to	  show	  the	  external	  validity	  of	  the	  study	  cohort	  [225].	  
Bronchoscopy	   cohort:	   The	   105	   patients	   that	   had	   a	   HRCT	   were	   asked	   to	   undergo	   a	  
bronchoscopy.	   Twenty-­‐four	   patients	   agreed	   to	   this	   at	   inclusion	  whereby	   bronchoalveolar	  
lavage	  (BAL)	  and	  bronchial	  biopsies	  were	  taken.	  Twenty-­‐one	  patients	  agreed	  to	  repeat	  the	  
investigation	  after	  6	  months.	  
COSMIC	  (Chronic	  Obstructive	  pulmonary	  disease	  and	  Smoking	  OMIC	  Perspective)	  cohort:	  A	  
control	   group	  of	  healthy	   individuals	   from	   the	   same	  geographical	   area	  and	   similar	  median	  
age	  and	  sex	  distribution	  as	  LURA	  cohort.	  These	  individuals	  were	  recruited	  by	  advertisement	  
at	   the	   Lung	   clinic	   at	   Karolinska	  University	  Hospital	   Solna	   as	   a	   control	   group	   to	   the	   COPD	  
study	   at	   the	   pulmonary	   clinic.	   Seventy-­‐nine	   included	   individuals	   underwent	   HRCT,	  
spirometry	  and	  bronchoscopy	  with	  BAL.	  As	  a	  control	  group	  to	  LURA	  in	  Paper	  I	  we	  used	  43	  
individuals	   from	  the	  COSMIC	  cohort	   that	  had	  a	  similar	  age	  and	  sex	  distribution	  as	  well	  as	  
smoking	  history.	  BAL	  from	  all	  79	  individuals	  in	  COSMIC	  were	  used	  as	  a	  control	  to	  the	  LURA	  
bronchoscopy	  cohort	  in	  Paper	  II.	  See	  patient	  characteristics	  for	  all	  cohorts	  in	  Table	  4.	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Table	  4.	  Characteristics	  of	  the	  subjects	  included	  in	  Papers	  I-­‐IV	  and	  EIRA	  cohort	  
	  









1430	   105	   43	   24	   79	   15	  
Female,	  %	   70	   67	   72	   46	   51	   40	  
















30	   26	   33	   21	   49	   60	  
Current-­‐
smoker,	  %	  
27	   29	   67	   42	   51	   40	  
ACPA+,	  %	   63	   67	   2	   75	   nd	   nd	  
RF+,	  %	   66	   68	   nd	   75	   nd	   nd	  
Median	  
DAS28	  
5.3	   5.4	   na	   4.9	   na	   na	  
na,	  not	  applicable;	  nd,	  not	  done	  
	  
3.2 METHODS	  
Investigations	  were	  performed	  at	  baseline	  before	  any	  anti-­‐rheumatic	  treatment	  was	  started	  
(Paper	  I-­‐III)	  and	  after	  6	  months	  of	  treatment	  (Paper	  IV).	  
High	   resolution	   computed	   tomography	   (HRCT):	   HRCT	   was	   performed	   using	   a	   Siemens	  
Sensation	  CT	  instrument	  at	  full	  inspiration	  and	  contiguous	  2mm	  images	  were	  reconstructed.	  
Images	   were	   independently	   reviewed	   for	   abnormalities	   by	   two	   blinded	   investigators	   in	  
accordance	   with	   the	   International	   Classification	   of	   HRCT	   for	   Occupational	   and	  
Environmental	  Respiratory	  Diseases	  criteria	  [226].	  Pathological	  changes	  were	  categorized	  as	  
i)	  parenchymal	  abnormalities;	  nodules	  larger	  than	  3	  mm,	  opacities,	  ground	  glass	  opacities,	  
fibrosis	   and/or	   emphysema,	   ii)	   airway	   abnormalities;	   bronchiectasis,	   air	   trapping	   and/or	  
bronchial	  wall	  thickening.	  	  
Lung	  function	  tests:	  patients	  performed	  a	  dynamic	  spirometry	  and	  body	  plethysmography.	  
Diffusing	   capacity	   for	   carbon	   monoxide	   (DLCO)	   was	   measured	   using	   the	   single-­‐breath	  
method	  and	  corrected	  for	  hemoglobin.	  	  
Bronchoscopy	  was	  performed	  to	  obtain	  bronchial	  biopsies	  and	  bronchoalveolar	  lavage	  fluid	  
(BALF).	  Bronchial	  biopsies	  were	  taken	   from	  segmental	  and	  subsegmental	   septa	  of	   the	   left	  
lung.	  For	  the	  BALF	  50	  ml	  x	  5	  of	  sterile,	  phosphate	  buffered	  saline	  solution	  was	  instilled	  and	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immediately	  aspirated.	  The	  handling	  of	  BAL	  fluid	  was	  completed	  as	  previously	  described	  in	  
detail	  [227].	  	  
Enzyme-­‐Linked	  ImmunoSorbent	  Assay	  (ELISA)	  (Papers	  I	  and	  III)	  	  
In	  Paper	  I	  we	  measured	  the	  levels	  of	  IgG	  ACPAs	  in	  both	  serum	  and	  BAL	  using	  a	  commercial	  
anti-­‐CCP-­‐2	  kit	  (Immunoscan	  RA	  Mark	  2;	  Euro-­‐Diagnostica)	  according	  to	  the	  manufacturer’s	  
instructions.	  We	  used	  the	  same	  kit	  with	  some	  modifications	  to	  the	  protocol	  to	  measure	  the	  
level	  of	  IgA	  ACPAs	  in	  serum	  and	  BAL	  as	  previously	  described	  [213].	  
In	  Paper	  III	  we	  established	  an	  in-­‐house	  ELISA	  to	  detect	  antibodies	  against	  newly	  identified	  
citrullinated	  vimentin.	  The	  cut-­‐off	  for	  positivity	  was	  determined	  using	  a	  population	  of	  152	  
healthy	  individuals	  and	  was	  set	  at	  98%	  specificity	  in	  arbitrary	  units	  per	  milliliter	  (AU/ml).	  
Immunohistochemistry	  (Papers	  I	  and	  II)	  
Bronchial	  biopsies	  were	  stained	  with	  biotinylated	  anti-­‐CCP	  antibodies	  generated	  in-­‐house	  
by	  affinity	  purification	  from	  a	  pool	  of	  synovial	  fluid	  of	  ACPA-­‐positive	  patients.	  Briefly,	  fluids	  
were	   first	   loaded	   onto	   a	   G	   column	   to	   isolate	   IgG	   and	   then	   purified	   on	   a	   CCP	   affinity	  
column	   to	   obtain	   CCP	   eluates	   (IgG	   anti-­‐CCP)	   and	   flow-­‐through	   fraction	   (IgG	   other	   than	  
anti-­‐CCP).	  Both	   fractions	  were	  biotinylated	  and	   then	  used	   for	  detection	  of	   citrullination,	  
the	  flow-­‐through	  being	  used	  as	  an	  irrelevant	  control.	  To	  further	  characterize	  the	  bronchial	  
tissues	  we	  performed	  immunohistochemistry	  for	  various	  cell	  type	  markers	  (T	  cells,	  B	  cells,	  
plasma	   cells,	   dendritic	   cells),	   immune	   activation	   markers	   (HLA-­‐DQ,	   HLA-­‐DR,	   activation-­‐
induced	   cytidine	   deiminase	   (AID))	   and	   PAD2.	   See	   Supplementary	   Table	   1	   in	   Paper	   II	   for	  
details	  on	  the	  antibodies	  used.	  
We	   used	   formaldehyde-­‐	   or	   acetone-­‐fixed	   cryostat	   sections	   of	   bronchial	   biopsies.	   We	  
started	  by	  blocking	  with	  hydrogen	  peroxide	  and	  then	  incubated	  with	  the	  primary	  antibody	  
according	  to	   the	  protocol	   for	   the	  antigen	  of	   interest.	  After	  washing	  we	  blocked	  with	  1%	  
serum	  from	  the	  same	  species	  as	   the	  secondary	  antibody	   is	  produced	   in	  order	   to	   reduce	  
background	   signal.	   Thereafter	   the	   peroxidase-­‐labeled	   secondary	   antibody	   was	   added.	  
After	   subsequent	   washes	   the	   slides	   were	   incubated	   with	   avidin-­‐biotin-­‐horseradish	  
peroxidase	   (Vectastain,	   ABC-­‐HP)	   kit.	   Colour	   reaction	   was	   developed	   by	   either	  
diaminobenzidine	   (DAB)	   substrate	   kits	   or	   AEC	   peroxidase	   (ImmPACT	   vector	   SK-­‐4205).	  
Counterstaining	   with	   hematoxylin	   revealed	   the	   nuclei	   of	   the	   cells	   and	   slides	   were	  
mounted	  with	  glycerol.	  In	  those	  cases	  that	  we	  wanted	  to	  detect	  intracellular	  antigens	  we	  
used	   saponin	   as	   a	   permeabilizing	   detergent.	   Results	   were	   analysed	   by	   a	   double-­‐blind,	  
semi-­‐quantitative	  evaluation	  mainly	  using	  a	  four-­‐point	  scale:	  0-­‐no	  staining,	  1-­‐low	  amount	  
of	  staining,	  2-­‐intermediate	  amount	  of	  staining	  and	  3-­‐high	  amount	  of	  staining.	  	  
Flow	  cytometry	  (Papers	  II	  and	  IV)	  
The	  expression	  of	   cell	   surface	  molecules	  was	   analysed	  using	   a	   fluorescence-­‐activated	   cell	  
sorter	   (FACS)	   CANTO	   II.	   BAL	   fluids	   were	   strained	   through	   a	   Dacron	   net	   (Millipore,	   Cork,	  
Ireland)	   and	   centrifuged.	  Cell	   pellets	  were	   then	   stained	   for	  CD4,	  CD8,	  CD25,	  CD27,	  CD28,	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CD69,	  CD103,	  CXCR3,	  HLA-­‐DR	  (antibodies	   from	  BD	  Biosciences,	  San	  Jose,	  CA,	  USA)	  and	  an	  
intracellular	  staining	  kit	  for	  FOXP3	  (eBioscience)	  as	  previously	  described	  [228].	  
Mass	  spectrometry-­‐based	  proteomics	  (Paper	  III)	  
The	  combination	  of	  liquid	  chromatography	  (LC)	  and	  mass	  spectrometry	  (MS)	  is	  a	  technique	  
that	  allows	  us	  to	  identify	  and	  characterize	  peptides	  and	  posttranslational	  modifications	  with	  
high	   specificity.	  We	   utilized	   this	   technique	   in	   Paper	   III	   to	   detect	   citrullinated	   peptides	   in	  
bronchial	   and	   synovial	   tissue	   from	   RA	   patients.	   A	   typical	   experiment	   comprised	   the	  









At	   first	   the	   tissues	   were	   homogenized	   by	   shaking	   with	   ceramic	   beads,	   after	   which	   the	  
homogenate	   was	   sonicated	   and	   centrifuged	   (protein	   extraction).	   After	   reduction	   and	  
alkylation	   the	   proteins	   were	   digested	   by	   a	   sequencing	   grade	   endoproteinase	   Lys-­‐C	  
(fragmentation).	  LC-­‐MS/MS	  were	  performed	  on	  an	  Easy-­‐nLC	  system	  (Thermo-­‐Scientific)	  on	  
line	   coupled	   directly	   to	   the	  mass	   spectrometer.	   The	   results	   from	   the	  mass	   spectrometer	  
were	  searched	  against	  a	  concatenated	  version	  of	  the	  human	  IPI	  database	  V.3.86	  using	  the	  
Mascot	  search	  engine	  (Matrix	  Science).	  	  
Statistical	  analyses	  
All	   the	  statistical	  analyses	  were	  performed	  using	  Statistica	  version	  10	   (Paper	   I)	  and	  Graph	  
Pad	  Prism	  5	  or	  6	  (GraphPad	  Software	  Inc.,	  San	  Diego,	  CA,	  USA)(Papers	  I-­‐IV).	   In	  the	  case	  of	  
descriptive	   statistics,	   data	  were	   presented	   as	  mean	  with	   standard	   deviation	   for	   normally	  
distributed	  variables	  and	  median	  with	  interquartile	  range	  (IQR)	  for	  nonparametric	  variables.	  
For	   comparison	   between	   groups	   with	   continuous	   variables	   the	   Mann-­‐Whitney	   U	   test	  
(nonparametric)	  or	  unpaired	   t-­‐test	   (normal	  distribution)	  were	  used.	  Wilcoxon	   signed	   rank	  
test	   and	   paired	   t-­‐test	  were	   used	  where	   appropriate	   for	   paired	   observations.	   Correlations	  
were	   analysed	   using	   the	   Spearman’s	   rank	   correlation	   test.	   When	   assessing	   categorical	  
variables	  we	  performed	  Chi-­‐square	  test	  when	  80%	  of	  the	  expected	  frequencies	  were	  at	  least	  
5,	  otherwise	  Fisher’s	  exact	  test	  was	  used.	  	  
Tissue	   Protein	  extract,	  
Digestion	  
Liquid	  chromatography	  
(separation	  of	  Peptides)	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In	  Paper	  I,	  which	  is	  a	  case-­‐control	  study,	  we	  used	  logistic	  regression	  to	  assess	  the	  influence	  
of	   potential	   predictive	   variables	   on	   the	   outcome	   (HRCT	   changes).	   The	   association	   is	  
presented	  as	  an	  odds	  ratio	  (OR)	  with	  95%	  confidence	  interval	  (CI).	  We	  started	  by	  performing	  
univariate	   logistic	   regression	   analysis	   to	   assess	   the	   causal	   role	   of	   various	   factors	   on	   the	  
presence	   of	   HRCT	   abnormalities.	   Subsequently	   we	   conducted	   a	   multivariate	   analysis	   to	  
examine	  which	  variable	  remained	  significant.	  	  
Comparisons	   between	   multiple	   groups	   were	   performed	   using	   analysis	   of	   variance,	   with	  
post-­‐hoc	  analysis	  using	  Tukey,	  Dunnett	  and/or	  Sidak	  test.	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4 RESULTS	  AND	  DISCUSSION	  
When	   we	   started	   the	   LURA	   study	   there	   was	   limited	   knowledge	   available	   regarding	   lung	  
involvement	   in	   early	   RA	   patients.	   As	   mentioned	   in	   the	   Introduction,	   lung	   changes	   often	  
accompany	   RA,	   due	   to	   the	   disease	   itself,	   infections	   or	   reactions	   following	   anti-­‐rheumatic	  
treatment.	   Previous	   studies	   in	   relatively	   early	   RA	   patients	   included	   patients	   that	   were	  
already	  receiving	  anti-­‐rheumatic	  treatment,	  thereby	  complicating	  the	  interpretation	  [51,	  53,	  
54,	  230].	  We	   initiated	   the	  LUng	   investigation	   in	  newly	  diagnosed	  RA	   (LURA)	   to	   shed	   light	  
onto	   the	   temporal	   relationship	   between	   lung	   involvement	   and	   onset	   of	   articular	   disease	  
before	   any	   treatment	   is	   started,	   and	   to	   investigate	   whether	   lung	   involvement	   differs	  
between	  subsets	  of	  RA.	  In	  addition	  we	  included	  a	  healthy	  control	  group	  to	  account	  for	  the	  
various	   changes	   detected	   by	  HRCT,	  which	  may	   not	   be	   of	   clinical	   relevance.	   Secondly,	  we	  
wanted	   to	   investigate	  our	  hypothesis	  of	  a	  potential	   role	  of	   the	   lungs	   in	   the	  generation	  of	  
autoimmunity/ACPA	  and	  thereby	  their	  role	  in	  the	  pathogenesis	  of	  RA.	  
4.1 PARENCHYMAL	  AND	  AIRWAY	  ABNORMALITIES	  ARE	  DETECTABLE	  EARLY	  IN	  PATIENTS	  
WITH	  UNTREATED	  RA	  (PAPER	  I)	  
We	  determined	  a	  higher	  frequency	  of	  both	  parenchymal	  and	  airway	  changes	  in	  our	  cohort	  
of	  newly	  diagnosed	  RA	  patients	  compared	  to	  the	  control	  group,	  54%	  of	  RA	  patients	  having	  
parenchymal	   changes,	   while	   only	   30%	   of	   controls	   did.	   Fibrosis	   (11%)	   and	   ground	   glass	  
opacities	  (7%)	  were	  only	  recorded	  in	  RA	  patients.	  Airway	  changes	  were	  apparent	  in	  66%	  of	  
RA	   group	   versus	   42%	   of	   the	   controls	   (Figure	   3).	   When	   stratified	   for	   ACPA	   there	   was	   a	  
significant	   difference	   between	   the	   presence	   of	   parenchymal	   changes	   in	   ACPA-­‐positive	  
patients	   (63%)	   as	   compared	   to	   ACPA-­‐negative	   patients	   (37%)	   and	   controls	   (30%).	   These	  
differences	  remained	  after	  compensation	  for	  smoking.	  No	  difference	  was	  evident	  regarding	  
ACPA	   positivity	   and	   negativity	   in	   terms	   of	   airway	   changes.	   However,	   the	   frequency	   of	  
bronchiectasis	   was	   slightly	   higher	   in	   ACPA-­‐positive	   patients	   compared	   to	   ACPA-­‐negative	  
patients	  although	  not	  statistically	  significant.	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A	   higher	   proportion	   of	   RA	   patients	   (though	   not	   significant)	   had	   airflow	   limitation	  
(FEV1/FVC<70%)	   compared	   to	   controls	   (36%	   versus	   21%),	   and	   reduced	  DLCO	   (defined	   as	  
<80%	  of	  predicted),	  52%	  as	  compared	  to	  45%	  in	  the	  control	  group.	  No	  difference	  was	  found	  
between	  ACPA-­‐positive	  and	  -­‐negative	  patients	  and	  no	  correlation	  was	  determined	  between	  
the	  findings	  of	  HRCT	  and	  lung	  function.	  
Using	  univariate	  analysis	  an	  association	  was	  found	  between	  parenchymal	  changes	  and	  age	  ≥	  
65	  years	  as	  well	   as	   the	  presence	  of	  ACPA.	  However,	  using	  multivariate	   logistic	   regression	  
ACPA	  remained	  the	  only	  significant	  predictor	  of	  parenchymal	  lung	  abnormalities.	  	  
The	  main	   drawback	   of	   this	   study	  was	   the	   somewhat	   inadequate	  matching	   of	   the	   control	  
group	   (Table	   4	   in	   section	   2.1)	   regarding	   smoking	   due	   to	   inclusion	   criteria	   in	   the	   COSMIC	  
study.	   Thus	  more	   current	   smokers	  were	   included	   in	   the	   control	   group	   and	   they	   also	   had	  
more	  pack	  years	  (median	  27)	  as	  compared	  to	  only	  11	  median	  pack	  years	  in	  the	  RA	  cohort.	  
Despite	  this,	  the	  control	  group	  did	  not	  have	  a	  worse	  ratio	  of	  FEV1/FVC,	  but	  they	  did	  report	  
more	   frequent	   cough	  and	  dyspnea	   than	  patients	   in	  our	   cohort	  during	   the	   last	  12	  months	  
prior	   to	   inclusion.	   As	   previously	   stated,	   no	   correlation	   was	   found	   between	   pulmonary	  
symptoms,	   HRCT	   changes	   or	   lung	   function	   tests	   but	   overall	   the	   difference	   in	   history	   of	  
smoking	  may	  affect	  our	   results	   and	  underestimate	   the	  differences	  of	   lung	  manifestations	  
between	  the	  groups.	  	  
Our	  results	  are	  in	  accordance	  with	  other	  previously	  mentioned	  studies	  of	  early	  RA	  patients,	  
which	  all	  described	  prevalent	   lung	  changes	  in	  these	  patients	  [51,	  53,	  54,	  230].	  The	  studies	  
are	  not	  quite	  consistent	  with	  respect	  to	  types	  of	  lung	  abnormalities,	  associations	  with	  ACPA	  
and	  duration	  of	  RA.	  Mori	  et	  al	  determined	  an	  association	  between	  interstitial	  abnormalities	  
and	  early	  RA,	  whereas	  airway	  abnormalities	  were	  more	  prominent	  in	  longstanding	  disease.	  
The	  study	  from	  Wilsher	  et	  al	  of	  60	  patients	  with	  symptom	  duration	  <	  1	  year	  and	  receiving	  
DMARDs	   recorded	   bronchiectasis	   in	   35%	   of	   patients	   and	   ground	   glass	   changes	   in	   18%.	  
Furthermore,	  Wilsher	  et	  al	  only	   reported	  an	  association	  of	  ACPA	  with	  bronchiolar	  disease	  
but	  not	  with	   interstitial	  disease.	  This	  concords	  with	  the	  study	  from	  Demoruelle	  et	  al,	  who	  
reported	   a	   higher	   prevalence	   of	   lung	   abnormalities,	   particularly	   airway	   inflammation,	   in	  
APCA-­‐positive	   healthy	   individuals	   at-­‐risk	   for	   RA	   as	   compared	   to	   ACPA-­‐negative	   at-­‐risk	  
individuals	   [231].	  Other	   studies	  both	   in	  patients	  with	   established	  RA	  and	   in	  patients	  with	  
lung	  disease	  and	  no	  joint	   inflammation	  have	  found	  strong	  correlations	  between	  titers	  and	  
numbers	   of	   ACPA	   specificities	   and	   lung	   disease,	   both	   interstitial	   and	   bronchiolar	  
involvement	  [107,	  119,	  120].	  	  
It	   is	   difficult	   to	   compare	   these	   studies	   as	   most	   of	   them	   are	   performed	   with	   patients	   of	  
longer	   duration	   of	   RA	   receiving	   anti-­‐rheumatic	   treatment.	   One	   possibility	   is	   that	   airway	  
disease	  is	  more	  associated	  with	  smoking	  status	  and	  parenchymal	  disease	  with	  ACPA	  status,	  
but	  this	  remains	  to	  be	  further	  investigated	  in	  even	  larger	  studies	  with	  careful	  consideration	  
of	   the	   smoking	   status.	   Further	   support	   of	   a	   specific	   association	   between	   ACPA	   and	  
parenchymal	  disease	   is	   that	   it	  has	  been	  shown	   that	  RA	  patients	  with	  associated	   ILD	  have	  
more	   ACPA	   specificities	   and	   higher	   ACPA	   titers	   [120].	   In	   accordance	   with	   this,	   our	  
preliminary	   results	   suggest	   that	   the	   more	   fine	   specificities	   exist,	   the	   more	   parenchymal	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changes	  are	  detectable	  on	  HRCT	  (Table	  5)	   (Joshua	  et	  al,	  poster	  ACR	  2015).	  This	   is	  not	   the	  
case,	  however,	  for	  airway	  changes.	  	  
Table	  5.	  Number	  of	  ACPA	  specificities	  associates	  with	  parenchymal	  changes	  
ACPA	  specificities	  (n)	   Patients	  (n)	   p-­‐value	   OR	  (95%	  CI)	  
0	   24	   Ref	   Ref	  
1-­‐3	   30	   0.03	   4.09	  (1.16	  -­‐	  14.38)	  
4-­‐6	   22	   0.02	   5.52	  (1.40	  –	  21.76)	  
>	  6	   27	   0.01	   5.75	  (1.53	  –	  21.63)	  
	  
Similarly,	   anti-­‐citrullinated	   fibrinogen	   and	   anti-­‐citrullinated	   vimentin	   reactivities	   appear	   to	  
be	   connected	   to	  parenchymal	   changes	  but	  not	   to	   airway	   changes	   (Table	  6)	   (Joshua	  et	   al,	  
poster	  ACR	  2015).	  	  
Table	  6.	  Specific	  ACPA	  fine	  specificity	  associates	  with	  parenchymal	  lung	  changes	  
	   Parenchymal	  changes	   Airway	  changes	  
ACPA	  specificity	   OR	   p	   OR	  (95%	  CI)	   p	  
Citrullinated	  fibrinogen	   5.0	  (1.8-­‐14.0)	   0.002	   1.1	  (0.4-­‐2.8)	   0.89	  
Citrullinated	  vimentin	   2.9	  (1.2-­‐7.4)	   0.03	   1.5	  (0.6-­‐3.7)	   0.34	  
Citrullinated	  enolase	   1.1	  (0.5-­‐2.5)	   0.78	   2.0	  (0.8-­‐5.1)	   0.15	  
	  
The	   lung	   function	   test	   results	   did	   not	   correlate	   with	   neither	   HRCT	   involvement	   nor	  
symptoms,	  which	  probably	   reflects	   the	  extent	  of	  pulmonary	  disease	  and	   is	   in	   accordance	  
with	  other	  studies	  that	  have	  shown	  at	  most	  modest	  correlation	  between	  airway	  disease	  and	  
lung	   function	   [54].	   In	   addition,	   another	   study	   reported	   no	   value	   of	   lung	   function	   tests	   in	  
predicting	  development	  of	  RA	  [232].	  
Taken	   together,	   this	   part	   of	   the	   study	   demonstrates	   a	   high	   frequency	   of	   airway	   and	  
parenchymal	  abnormalities	  in	  RA	  patients	  already	  at	  diagnosis,	  and	  of	  particular	  interest	  is	  
the	  association	  between	  the	  presence	  of	  ACPA	  and	  parenchymal	  changes.	  The	  fact	  that	  no	  
correlation	  was	   found	  between	   the	  HRCT	   changes,	   lung	   function	  and	   symptoms	   supports	  
the	   notion	   that	   these	   abnormalities	   are	   subclinical.	   However,	   this	   also	   emphasizes	   the	  
importance	  of	  learning	  more	  about	  the	  natural	  development	  of	  these	  lung	  abnormalities	  as	  
well	   as	   responses	   to	   treatment.	   Additionally,	   these	   findings	   underscore	   the	   need	   for	  
awareness	   of	   potential	   early	   lung	   involvement	   and	   for	   rheumatologists	   to	   have	   a	   low	  
threshold	  to	  actively	   look	   for	  potential	   lung	  disease	   (preferably	  by	  conducting	  HRCT).	  This	  
knowledge	  also	  highlights	  the	  importance	  of	  implementing	  smoking	  cessation	  programs	  for	  
patients	  with	  RA.	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4.2 SIGNS	  OF	  INFLAMMATION	  AND	  IMMUNE	  ACTIVATION	  ARE	  PRESENT	  IN	  THE	  LUNGS	  
OF	  EARLY	  UNTREATED	  RA	  (PAPERS	  I	  AND	  II)	  
Previous	   studies	   of	   lung	   histology	   and	   immunology	   in	   RA	   have	   focused	   on	   patients	   with	  
longstanding	   RA	   and	   concomitant	   lung	   disease.	   These	   studies	   have	   reported	   more	  
lymphocyte	   infiltrates	   in	   the	   lungs	   of	   these	   patients	   as	   compared	   to	   lung	   biopsies	   from	  
patients	  with	  solely	  lung	  disease	  but	  not	  RA	  [223,	  233,	  234].	  In	  addition,	  signs	  of	  inducible	  
bronchus-­‐associated	  lymphoid	  tissue	  (iBALT)	  with	  germinal	  centers	  and	  B	  cells	  that	  bound	  to	  
citrullinated	   proteins	   have	   been	   demonstrated,	   indicating	   the	   possibility	   that	   antibodies	  
against	  citrullinated	  proteins	  may	  be	  produced	  in	  the	  lungs	  [223].	  	  
As	   discussed	   in	   the	   etiopathogenesis	   chapter,	   multiple	   factors	   point	   to	   the	   lung	   as	   an	  
initiating	   site	   of	   autoimmunity	   in	   RA.	   Smoking	   and	   other	   airway	   exposure	   can	   induce	  
citrullination	   and	   activate	   the	   innate	   immune	   system	   [220,	   221,	   235],	   changes	   in	  
microbiome	   may	   contribute	   to	   autoimmunity	   [160,	   161],	   and	   an	   IgA	   ACPA	   response	   is	  
apparent	  early	  during	   the	  development	  of	  ACPA	   immunity	   [212-­‐214].	  Furthermore,	  as	  we	  
demonstrated	   in	   Paper	   I,	   the	   strong	   association	   between	   ACPA	   and	   early	   lung	  
manifestations	  may	  suggest	  the	  lung	  as	  an	  early	  player	  in	  the	  development	  of	  RA.	  
We	  found	  more	  lymphocytic	  infiltration	  in	  the	  lungs	  of	  ACPA-­‐positive	  RA	  patients	  (9/18)	  as	  
compared	  to	  ACPA-­‐negative	  patients	  (1/6),	  p>0.05	  and	  controls	  (2/15),	  p<0.05.	  In	  2/9	  ACPA-­‐
positive	  patients	   the	   lymphocytic	   infiltration	  resembled	  germinal-­‐like	  structures	  and	  these	  
were	   positive	   for	   B	   cells,	   activation-­‐induced	   cytidine	   deaminase	   (AID)	   and	   biotinylated	  
citrullinated	  enolase.	  	  B	  cells	  and	  plasma	  cells	  were	  only	  found	  in	  the	  lungs	  of	  ACPA-­‐positive	  
patients	  and	  T	  cells	  were	  somewhat	  more	  common	  in	  ACPA-­‐positive	  versus	  ACPA-­‐negative	  
patients.	   The	   expression	   of	   immune	   activation	  markers	   such	   as	  HLA-­‐DR	   and	  HLA-­‐DQ	  was	  
significantly	  higher	  in	  ACPA-­‐positive	  patients	  compared	  to	  in	  ACPA-­‐negative.	  	  
In	   BAL	   we	   found	   higher	   relative	   numbers	   of	   lymphocytes	   and	   neutrophils	   and	   lower	  
numbers	  of	  macrophages	  in	  ACPA-­‐positive	  patients	  compared	  to	  in	  ACPA-­‐negative	  patients.	  
The	  same	  was	  true	  when	  we	  compared	  smoking	  ACPA-­‐positive	  patients	  to	  smoking	  controls.	  
More	   activated	   T	   cells	   were	   identified	   in	   BAL	   of	   ACPA-­‐positive	   patients	   compared	   to	  
controls.	  	  
We	   detected	   increased	   expression	   of	   PAD2	   in	   BAL	   of	   ACPA-­‐positive	   patients	   and	   higher	  
expression	  of	   citrullinated	  proteins	   in	   the	   lungs	  of	  ACPA-­‐positive	  patients	   compared	   to	   in	  
ACPA-­‐negative	  patients,	  being	  especially	  high	   in	  ACPA-­‐positive	  smokers.	  This	   is	  partially	   in	  
concordance	  with	  previous	  results	  from	  our	  group,	  whereby	  higher	  expression	  of	  PAD2	  and	  
citrullinated	   proteins	   was	   detected	   in	   the	   lungs	   of	   smokers	   compared	   to	   never	   smokers	  
[235].	  However,	  here	  we	  also	  recorded	  an	  association	  between	  citrullination	  and	  presence	  
of	   ACPA	   in	   the	   non-­‐smokers,	   suggesting	   that	   other	   factors	   than	   smoking	   (such	   as	   local	  
injuries	  due	  to	  irritants	  and/or	  inflammation)	  might	  be	  responsible	  for	  this	  finding.	  	  
We	  identified	  higher	  relative	  levels	  of	  ACPAs	  in	  BALF	  as	  compared	  with	  paired	  serum	  in	  our	  
patient	  cohort	  with	  early,	  untreated	  RA	  (Figure	  4).	  	  







This	  enrichment	  suggests	  a	  local	  production	  of	  antibodies	  in	  the	  lungs	  of	  these	  patients	  and	  
in	  support	  of	  this	  is	  a	  study	  from	  Willis	  et	  al	  that	  detected	  the	  presence	  of	  ACPAs	  and	  RF	  in	  
the	  sputum	  of	  at-­‐risk	  RA	  patients,	  some	  of	  whom	  did	  not	  yet	  have	  these	  antibodies	  in	  the	  
serum	   [236].	   In	   addition,	   an	   association	   between	   presence	   of	   antibodies	   to	   citrullinated-­‐
heat	  shock	  protein	  90	  (hsp90)	  in	  both	  BAL	  fluid	  and	  serum,	  and	  RA-­‐ILD	  has	  been	  reported.	  
These	  antibodies	  against	  hsp90	  were	  not	  as	  frequent	  in	  RA	  alone	  and	  were	  not	  detected	  at	  
all	   in	   patients	   with	   idiopathic	   pulmonary	   fibrosis	   [237,	   238].	   We	   know	   that	   ACPAs	   are	  
probably	  not	  present	  in	  an	  uninflamed	  joint	  (no	  signs	  of	  immune	  activation	  or	  inflammation	  
in	   pre-­‐clinical	   studies)	   although	   they	   are	   present	   in	   serum	   before	   the	   clinical	   onset	   of	  
disease	  [211].	  Thus	  the	  production	  of	  ACPAs	  is	   initiated	  outside	  of	  the	  joint	  and	  in	  certain	  
groups	  of	  patients	  this	  could	  be	  the	  lung.	  Independently	  of	  the	  origin	  and	  source	  of	  ACPAs	  
early	  on,	   the	  production	  of	  ACPAs	  eventually	   takes	  place	   in	   the	   joints	  of	  patients.	   Finally,	  
these	  indications	  of	  ACPA	  production	  in	  the	  lungs	  need	  to	  be	  further	  proven	  by	  isolation	  of	  
ACPA-­‐producing	  B	  cells	  from	  BAL.	  We	  are	  currently	  attempting	  to	  do	  this	  using	  our	  previous	  
strategy	  of	  isolating	  single	  B	  cells	  and	  cloning	  of	  their	  antibodies	  [186].	  
Taken	   together,	   our	   findings	   further	   support	   the	   hypothesis	   that	   the	   lung	   might	   be	   an	  
initiating	   organ	   of	   autoimmunity	   in	   a	   subset	   of	   individuals,	  which	  may	   ultimately	   lead	   to	  
clinical	  RA.	  Hopefully	  we	  are	  getting	  closer	  to	  an	  initiation	  of	  interventional	  studies	  to	  try	  to	  
suppress	   the	   possible	   progression	   of	   inflammation,	   citrullination	   and	   anti-­‐citrulline	  
immunity	  in	  the	  lungs.	  	  
4.3 SHARED	  CITRULLINATED	  TARGETS	  ARE	  PRESENT	  IN	  THE	  LUNGS	  AND	  JOINTS	  OF	  RA	  
PATIENTS	  (PAPER	  III)	  
The	   aim	  of	   Paper	   III	  was	   to	   look	   for	   a	   shared	   antigen	  between	   lung	   and	   joint	   tissue	   that	  
could	  further	  strengthen	  our	  hypothesis	  of	  a	  disease	  initiated	  in	  the	  lung	  and	  subsequently	  
leading	  to	  inflammation	  in	  the	  joints.	  
We	   detected	   10	   citrullinated	   peptides	   from	   7	   proteins	   by	   MS/MS.	   Eight	   citrullinated	  
peptides	  were	  found	  in	  synovial	  biopsies	  and	  7	  in	  bronchial	  biopsies	  with	  5	  peptides	  being	  
shared	  between	  the	  two	  tissue	  samples	  sites.	  Two	  out	  of	  these	  five	  identified	  citrullinated	  
peptides	  were	  present	  in	  the	  majority	  of	  both	  synovial	  and	  bronchial	  biopsies:	  cit-­‐vim	  446-­‐




































Figure	  4.	  Enrichment	  of	  
ACPAs	  in	  BAL	  fluids	  of	  ACPA-­‐
positive	  early	  RA	  patients	  
  34 
identified	   in	   5/6	   bronchial	   samples	   and	   all	   synovial	   tissue	   samples.	   The	   10	   citrullinated	  
peptides	  identified	  by	  MS/MS	  are	  presented	  in	  Table	  7.	  
Table	  7.	  Quantification	  of	  citrullinated	  peptides	  in	  lung	  and	  joint	  tissue.	  	  
ND-­‐neither	  citrullinated	  nor	  unmodified	  were	  detected,	  0-­‐only	  unmodified	  peptide	  detected,	  NS-­‐nonsmoker,	  	  
S-­‐smoker	  	  
Detecting	   a	   citrullination	   in	   a	   tissue	   is	   a	   major	   challenge	   as	   this	   post-­‐translational	  
modification	   causes	   a	   mass	   shift	   of	   0.9840	   Da,	   which	   is	   the	   same	   mass	   shift	   caused	   by	  
deamidation,	   which	   occurs	   quite	   commonly	   both	   in	   vivo	   and	   in	   vitro.	   Furthermore,	   the	  
results	   from	   our	   study	   as	   well	   as	   others	   have	   determined	   that	   citrullination	   is	   of	   low	  
abundance	   in	   tissues,	  which	  poses	  even	  bigger	  challenges	  as	  we	  know	  that	   the	  quality	  of	  
MS/MS	  is	  correlated	  to	  the	  abundance	  of	  the	  peptide	  of	  interest	  [239].	  
We	   could	   not	   detect	   any	   of	   the	   10	   citrullinated	   peptides	   identified	   in	   RA	   patients	   in	   the	  
bronchial	  biopsies	  from	  non-­‐RA	  non-­‐smokers,	  while	  a	  weak	  signal	   for	  cit-­‐vim	  446-­‐466	  was	  
observed	   in	   non-­‐RA	   smoker	   bronchial	   biopsies.	   We	   detected	   a	   higher	   ratio	   of	  
citrullinated/unmodified	  cit-­‐vim	  446-­‐466,	  although	  this	  was	  not	  significant,	  in	  the	  bronchial	  
biopsies	   from	   RA	   smokers	   compared	   to	   non-­‐smokers,	   which	   agrees	   with	   our	   and	   others	  
previous	   results	   showing	   a	   higher	   expression	   of	   citrullination	   in	   the	   lungs	   of	   smokers	  
compared	  to	  non-­‐smokers	  [235,	  240].	  
The	  detection	  of	  cit-­‐vimentin	  as	  the	  only	  citrullinated	  peptide	  present	  in	  non-­‐RA	  smokers	  is	  
an	   interesting	   finding.	   It	   does	   not	   rule	   out	   the	   presence	   of	   lower	   amounts	   of	   other	  
citrullinated	   peptides,	   but	   one	   can	   speculate	   that	   smoking	   first	   induces	   citrullination	   of	  
vimentin	   and	   subsequently,	   with	   continuous	   stimulation	   and	   activation	   of	   the	   innate	  
immune	  system,	  other	  peptides	  may	  become	  citrullinated.	  This	  can	  add	  to	  the	  inflammatory	  
burden	   by	   formation	   of	   immune	   complexes,	   more	   tissue	   destruction	   and	   production	   of	  
cytokines,	  which	  may	  lead	  to	  an	  immune	  response	  in	  genetically	  susceptible	  individuals.	  	  
But	   do	   these	   newly	   identified	   citrullinated	   peptides	   provoke	   an	   immune	   response?	   As	  
mentioned	   earlier,	   citrullination	   is	   a	   non-­‐specific	   physiological	   process	   and	   without	   an	  
Actin Annexin A2 Cysteine-rich Hemoglobin Histone
 protein 1 subunit α  H3.1t
 62-68  47-65  10-22  449-463  559-575  582-599  129-142  25-37  440-455  446-466
0 0 N.D. 0.012 N.D. 0 N.D. N.D. 0.019 0
0 0 0 0.007 0.050 0 0 0 0.003 0.002
0 0 0 0 0.130 0 0 0 0.002 0.004
0 0 0 0 0.102 0 0 0 0.011 0.012
0.003 0.072 0 0 0 0 0 0 0.014 0.006
0 0.064 0 0 0 0 0 0 0.001 0.002
0.003 0 0 0.048 0.387 0.220 0 0.363 0.024 0.054
Lung 1 NS 0 0.085 0 N.D. N.D. 0 N.D. N.D. 0.026 0.039
Lung 2 NS 0 0.099 0 N.D. 0 0 N.D. 1.360 0.006 0.012
Lung 3 NS 0.003 0.074 0.113 N.D. N.D. N.D. 0 N.D. 0.180 0.568
Lung 4 S 0 0.145 0 N.D. 0 0 N.D. 3.654 0.030 0.025
Lung 5 S 0.089 0.130 0 N.D. N.D. N.D. 0.163 N.D. 0.281 1.260
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immune	   response	   against	   the	   citrullinated	   peptides	   it	   probably	   remains	   undetectable.	   To	  
investigate	  the	  relevance	  of	  these	  shared	  cit-­‐vim	  peptides	  we	  set	  up	  an	  ELISA	  against	  both	  
native	   and	   citrullinated	   forms	   of	   the	   peptide.	   The	   cut-­‐off	  was	   set	   at	   the	   98	  percentile	   of	  
reactivity	   using	   a	   healthy	  population	  of	   152	   individuals.	   In	   our	   LURA	   cohort	   14.9%	  of	   the	  
patients	  showed	  immune	  reactivity	  against	  the	  citrullinated	  peptide,	  23.4%	  of	  the	  anti-­‐CCP	  
positive	   group	   whereas	   only	   2.6%	   of	   the	   anti-­‐CCP	   negative	   group.	   Regarding	   association	  
with	  the	  shared	  epitope,	  85%	  of	  the	  patients	  that	  showed	  reactivity	  to	  this	  peptide	  had	  the	  
shared	   epitope	   compared	   to	   71%	   of	   patients	   that	   did	   not	   show	   reactivity.	   This	   is	   in	  
agreement	  with	  other	  studies	  which	  have	  reported	  an	  association	  between	  the	  presence	  of	  
the	  shared	  epitope,	  smoking	  and	  ACPA	  specificities	  [189,	  194].	  
The	  main	  drawback	  of	   this	   study	  was	   the	   lack	  of	  paired	   lung	  and	   synovial	   tissue	   samples	  
from	   the	   same	   patients	   and	   limited	   numbers	   of	   samples.	   This	   is	   obviously	   due	   to	   the	  
challenge	   of	   recruiting	   patients	   to	   interventional	   studies.	   Nevertheless,	   these	   are	   unique	  
bronchial	   tissue	   samples	   from	   patients	   with	   very	   early	   RA,	   naïve	   to	   anti-­‐rheumatic	  
treatment	   (neither	   DMARD	   nor	   glucocorticoids).	   Regarding	   the	   potential	   bias	   by	   using	  
synovial	  tissue	  from	  patients	  with	  longstanding	  and	  treated	  RA,	  previous	  studies	  of	  patterns	  
of	   citrullination	   in	   synovium	   have	   shown	   similar	   results	   in	   new	   onset	   and	   longstanding	  
patients	  [175,	  177,	  178,	  241].	  
The	  main	  finding	  here	  is	  that	  we	  identified	  citrullinated	  vimentin	  that	  was	  shared	  between	  
the	  majority	  of	  lung	  and	  joint	  tissue	  samples,	  and	  immune	  responses	  against	  this	  antigen	  in	  
RA	  patients.	  This	  indicates	  a	  potential	  link	  between	  the	  origin	  of	  autoimmunity	  in	  the	  lung,	  
which	   eventually	   induces	   pathology	   in	   another	   target	   organ	   of	   effect,	   the	   joints.	   These	  
findings	  of	   different	   citrullinated	  peptides	   in	   the	   lungs	   and	   joints,	   further	   emphasizes	   the	  
need	  to	  identify	  and	  compare	  the	  presence	  of	  citrullinated	  proteins	  in	  different	  organs	  and	  
to	  look	  for	  associations	  to	  possible	  etiological	  factors.	  	  
4.4 HRCT	  ABNORMALITIES	  DETECTED	  AT	  DISEASE	  ONSET	  ARE	   STILL	   PRESENT	  AFTER	   6	  
MONTHS	  OF	  TREATMENT	  AND	  OCCASIONALLY	  PROGRESS	  (PAPERS	  I	  AND	  IV)	  
The	  6-­‐month	  follow-­‐up	  study	  gave	  us	  the	  opportunity	  to	  gain	  knowledge	  of	  the	  longitudinal	  
history	  of	  subclinical	  lung	  abnormalities	  in	  RA,	  both	  before	  and	  after	  initiation	  of	  treatment.	  
A	  longer	  follow-­‐up	  would	  of	  course	  be	  even	  more	  informative	  and	  we	  are	  currently	  planning	  
for	  the	  10-­‐year	  follow-­‐up.	  	  
The	   majority	   of	   patients	   in	   LURA	   started	   treatment	   with	   methotrexate	   (MTX)	   (92%)	   in	  
combination	  with	  glucocorticoids	   (80%)	   in	   accordance	  with	   clinical	   guidelines	   [37].	  Of	   the	  
105	  patients	  that	  underwent	  HRCT	  at	  baseline,	  93	  patients	  (89%)	  repeated	  it	  at	  six	  months.	  	  
Lung	   function	   tests	  were	  conducted	   in	  108	  patients	  at	   follow-­‐up	   (out	  of	  135	  at	  baseline).	  
Twenty-­‐one	  of	   the	  24	  patients	   at	  baseline	  agreed	   to	  undergo	  another	  bronchoscopy	  at	  6	  
months.	  
At	  baseline	  12	  patients	  had	  evident	  fibrotic	  changes	  on	  HRCT	  and	  at	  6	  months	  every	  third	  
patient	   (4/12)	   had	   evidence	   of	   radiological	   progression.	   An	   additional	   three	   patients	   had	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developed	  fibrosis	  at	  follow-­‐up.	  This	  is	  in	  accordance	  with	  other	  studies	  that	  have	  reported	  
progressive	   RA-­‐ILD	   in	   34-­‐57%	   of	   patients	   within	   2	   years	   of	   follow-­‐up	   [52,	   118].	  	  
Patients	   that	   had	   progressive	   fibrosis	   (n=4)	   were	   treated	   with	   the	   target	   MTX	   dose	  
(20mg/week)	  and	  presented	  with	  ground	  glass	  changes	  at	  baseline.	  Despite	  the	  fact	  that	  all	  
patients	  with	  progressive	  fibrosis	  received	  high	  doses	  of	  MTX,	  no	  conclusions	  can	  be	  made	  
for	  a	  potential	  role	  of	  MTX.	  In	  this	  respect	  it	  is	  important	  to	  mention	  that	  a	  large	  majority	  of	  
the	   patients	   were	   treated	   with	   this	   high	   dose	   although	   they	   never	   developed	   signs	   of	  
fibrosis	  at	   follow-­‐up.	  Despite	  a	  previous	   study	   implied	   that	  MTX	  might	  be	  a	  potential	   risk	  
factor	  for	  lung	  fibrosis,	  this	  was	  not	  statistically	  significant	  [52].	  Notably,	  a	  causal	  association	  
between	   MTX	   and	   chronic	   pulmonary	   fibrosis	   was	   not	   apparent	   in	   a	   large	   study	   from	  
Dawson	  et	  al,	  although	  the	  mean	  MTX	  dose	  in	  that	  study	  was	   lower	  (10.7	  mg/week)	  than	  
recommended	  doses	  for	  RA	  [92].	  Previous	  studies	  have	  shown	  an	  association	  between	  RA-­‐
ILD	  and	  high	   titers	  of	  ACPA	   [101,	  108,	  109].	   Two	  out	  of	   four	  progressive	   cases	  of	   fibrosis	  
presented	   herein	   had	   high	   levels	   of	   ACPA	   and	   all	   patients	   were	   treated	   with	   high	   MTX	  
doses.	   These	   numbers	   are	   still	   too	   low	   to	   enable	   drawing	   any	   causality	   conclusion.	  	  
No	  other	  differences	  in	  changes	  on	  HRCT	  between	  baseline	  and	  follow-­‐up	  were	  observed.	  
We	  found	  a	  large	  decline	  in	  FEV1	  in	  all	  patients	  at	  six	  months	  follow-­‐up.	  No	  association	  with	  
the	   presence	   or	   absence	   of	   ACPA	   was	   observed.	   Most	   prominent	   was	   the	   reduction	   in	  
smokers	  (mean	  decline	  150	  ml),	  but	  even	  in	  the	  group	  of	  non-­‐smokers	  a	  significant	  loss	  of	  
function	  occurred	   (30	  ml).	  Normally,	   a	   decline	   in	   FEV1	  occurs	  with	   aging,	  with	   an	   annual	  
decline	   in	   smokers	   of	   about	   50-­‐60	  ml,	   while	   in	   non-­‐smokers	   this	   is	   around	   20	  ml	   [242].	  
This	   large	   decline	   in	   FEV1,	   particularly	   in	   smokers,	   may	   imply	   an	   ongoing	   airway	  
inflammation	  and	  is	  a	  concern	  as	  many	  patients	  may	  eventually	  develop	  COPD,	  which	  will	  
further	  add	  to	  the	  morbidity	  and	  increased	  mortality	  observed	  in	  these	  patients	  [78,	  243].	  
Analysis	   of	   the	   immunological	   phenotype	   in	   BAL	   fluids	   revealed	   a	   predominance	   of	   the	  
lymphocytes	   and	   neutrophils	   at	   baseline	   that	   was	   not	   significantly	   changed	   following	  
therapy,	  consistent	  with	  a	  picture	  of	  immune	  activation	  and	  inflammation	  in	  the	  lungs	  that	  
might	   continue	   despite	   successful	   anti-­‐rheumatic	   treatment	   with	   conventional	   DMARD	  
(here	  MTX)	  and	  oral	  glucocorticoids.	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5 CONCLUSIONS	  OF	  THE	  THESIS	  
• Lung	   involvement	   is	   prevalent	   in	   early,	   untreated	   rheumatoid	   arthritis	   patients	   with	  
both	  airway	  and	  parenchymal	  abnormalities	  being	  more	  frequent	  compared	  to	  matched	  
healthy	  controls.	  	  
• Lung	  involvement	  in	  early	  RA	  may	  already	  be	  progressive	  at	  6	  months	  follow-­‐up,	  despite	  
successful	  anti-­‐rheumatic	  treatment.	  
• The	   presence	   of	   ACPA	   strongly	   associates	   with	   subclinical	   parenchymal	   lung	  
abnormalities	  independently	  of	  smoking.	  
• Signs	  of	  inflammation	  and	  immune	  activation	  with	  concomitant	  increased	  citrullination	  
and	   ACPA	   enrichment	   are	   present	   in	   both	   lung	   compartments	   of	   ACPA-­‐positive	   early	  
untreated	  RA	  patients.	  
• Shared	   novel	   citrullinated-­‐vimentin	   targets	   are	   present	   in	   a	  majority	   of	   the	   lung	   and	  
synovial	  tissue	  samples	  investigated.	  	  
• Specific	   immunity	   against	   the	   novel	   citrullinated-­‐vimentin	   peptides	   is	   specifically	  
detected	  in	  the	  blood	  of	  RA	  patients.	  
	  
	  
• Taken	  together	  our	  results	  raise	  awareness	  for	  the	  potential	   lung	  involvement	  in	  early	  
RA	  and	  give	  further	  support	  for	  the	  role	  of	  lungs	  as	  an	  initiating	  organ	  of	  autoimmunity	  
in	  RA.	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  Sigga,	  who	  always	  comes	  up	  with	  good	  ideas	  like	  this	  one.	  	  
My	  ASA	  sisters,	  Sigga,	   Guðrún,	   Arna	   and	   Sunna,	   for	  always	  being	  dear	  and	  good	   friends.	  
Thank	  you	  especially	  these	  last	  months	  for	  understanding,	  endless	  pep-­‐talks,	  and	  supporting	  
me	  in	  many	  different	  ways.	  Guðrún,	  my	  dear	  friend	  ever	  since	  the	  first	  weeks	  in	  Stockholm,	  
what	  a	  historical	  moments	  we	  have	  had	   together.	  Thank	  you	  Sunna,	   for	  all	   your	  amazing	  
help	   during	   my	   thesis	   writing,	   for	   all	   the	   good	   advices	   and	   editing,	   emotional	   support	  
(always)	  and	  for	  being	  such	  a	  good	  friend,	  trying	  to	  make	  me	  belief	  I	  am	  doing	  fine	  –	  though	  
you	  will	  have	  to	  do	  better	  than	  this	  :)	  And	  also	  for	  yours	  and	  Sigurður	  Yngvis	  friendship,	  we	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can	  always	  rely	  on	  you,	  whether	   it	  means	  moving	  from	  Reykjavík	  to	  Stockholm	  or	  moving	  
from	  Stockholm	  to	  Reykjavík,	  and	  for	  making	  us	  party	  until	  dawn!	  	  
Nathalía	  and	   Ingi,	  my	  wonderful	  dear	  friends	  and	  now	  neighbours!	  It	  feels	  just	  right	  to	  live	  
in	   the	   next	   house,	   looking	   forward	   to	   spending	   more	   time	   with	   you,	   be	   it	   long	   walks,	  
exercising	  or	  dinner	  parties	  (preferred).	  	  
Anton,	  Fjóla,	  Arnar	  and	  Svandís,	  for	  great	  friendship	  and	  fun	  the	  last	  20	  years	  –	  now	  it	  is	  our	  
turn!	  We’ll	   host	   the	   next	   dinner	   party.	   Thank	   you	  Anton,	   for	   your	   appreciated	   help	  with	  
Microsoft	  Word.	  
My	  in-­‐laws,	  Hanna	  María	  and	   Jói,	  for	  being	  so	  genuine	  and	  true.	  You	  are	  one	  of	  the	  most	  
understanding	   and	  well-­‐balanced	   people	   I	   know	   and	   I	   am	   so	   grateful	   to	   be	   part	   of	   your	  
family.	  
Jóhanna	  and	  family,	  for	  being	  such	  fun	  people	  to	  be	  with	  and	  thank	  you	  for	  your	  marathon	  
visits	  in	  Stockholm,	  just	  for	  strenghtening	  our	  families	  relationship	  –	  it	  meant	  a	  great	  deal	  to	  
me	  and	  my	   family!	  We	  miss	   you!	  And	   thank	  you	  my	  dear	   sister	   for	  believing	   in	  me	   from	  
childhood	  even	  though	  I	  could	  be	  quite	  irritating	  at	  times.	  
Einar	  Daði,	  my	  brother,	  for	  your	  support	  through	  all	  times.	  
My	  parents,	  Þóra	   and	  Reynir,	   for	  your	   love,	  encouragement	  and	  believing	   in	  me	   in	  every	  
situation.	  	  
My	  children,	  Reynir,	  Freyja	  and	  Þórey	  Hanna,	  for	  giving	  me	  new	  perspectives	  on	  life.	  I	  am	  so	  
proud	  of	  you	  –	  always.	   I	  am	   looking	  forward	  to	  spend	  more	  time	  with	  you	  –	   	   though	  you	  
may	  not.	  I	  love	  you	  more	  than	  you	  can	  ever	  imagine.	  	  
My	   husband,	  Diddi,	   for	   everything.	   Your	   positivity,	   optimism	   (at	   times	   a	   bit	   exhausting),	  
pep-­‐talks	   and	   patience	   with	   the	   children	   (and	   me)	   have	   carried	   me	   through	   these	   last	  
weeks.	  You	  are	  the	  best!	  I	  am	  so	  looking	  forward	  to	  our	  lifetime	  together,	  xxxxxxxxxxxxxxxxx	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